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Immunotherapy is revolutionizing cancer treatment achieving durable and
long-term responses in patients. However, only subsets of patients treated
experience a positive outcome, due to immunotherapeutic resistance.
Combinations of immunotherapeutics can overcome the drug resistance; the
administration of a cancer vaccine or an oncolytic virus followed by immune
checkpoint inhibitors is under investigation. Thereby, there is an unmet need
for powerful, yet safe vaccines. Nanoparticles, in particular porous silicon
nanoparticles, present ideal characteristics to formulate nanovaccines, thanks
to their size-specific targeting to the lymphoid organs, to their intrinsic
adjuvant effect, and to the possibility to simultaneously load adjuvants and
antigens. Moreover, biohybrid cell membrane technology has been proposed
as an innovative antigenic source. Thus, the aims of the current thesis were to
develop a biohybrid multistage nanovaccine formulation and to evaluate its
anticancer efficacy in murine tumor models. Firstly, the parameters affecting
the formulation of the biohybrid nanosystems were assessed, along with the
elucidation of the influence of the cell membrane coating on the colloidal
stability in physiological conditions and on the biocompatibility in different
cell types. Secondly, the effect of the cell membrane-wrapping on the cellular
uptake was evaluated in the presence of inhibitors of selective uptake
pathways, to assess the differences between naked and coated nanoparticles.
Then, a multistage nanovaccine was engineered by glass capillary
microfluidics, followed by the cloaking with the cell membrane. The
immunological profile of the nanovaccine was investigated in vitro, assessing
the expression of co-stimulatory signals and the secretion of proinflammatory
cytokines. The efficacy of the biohybrid nanovaccine as a monotherapy and in
combination with an immune checkpoint inhibitor was then evaluated in
melanoma murine models. Finally, the adjuvant core was changed from
synthetic nanoparticles to oncolytic adenoviruses to investigate the
translatability of the technique, the influence of the cell membrane-coating on
the viral infectivity, and the preventive and therapeutic efficacy of the vaccine
in different tumor models. Overall, porous silicon and adenovirus-based
biohybrid nanovaccines were developed, providing new insights on the
structure and efficacy of these systems as therapeutic cancer nanovaccines.
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1 Introduction
Immunotherapy has surged to the honors as a novel concept in cancer
therapy with long-term results in subsets of patients treated with monoclonal
antibodies or with adoptive cell therapy 1,2. However, primary and acquired
resistance undermines the efficacy of these treatments 3. Cancer vaccines and
oncolytic viruses prime antigen-specific immune responses against tumor
associated antigens with potential advantageous combinations with other
immunotherapeutics 4-6.
Nanoparticles (NP) represent ideal candidates for vaccine formulation
as a result of their properties (e.g., size, shape, and surface characteristics) and
of the possibility to simultaneously load and deliver antigens and adjuvants 7,8.
Moreover, nanosystems can present intrinsic adjuvant properties brought
along by the material, the responsiveness to intracellular stimuli, and the
resemblance to viral and bacterial structures 9-12. Porous silicon (PSi)
represents an innovative material for the development of drug delivery
systems, enabling the delivery of poorly soluble drugs 13-18. Moreover, this
material is characterized by a surface-dependent interaction with the cells of
the immune system, from immunoneutral to immunostimulatory 11.
Despite the abovementioned advantages, NPs suffer from problems in
colloidal stability in physiological-relevant media, formation of a protein
corona, and unwanted interactions with cells of the reticuloendothelial system
(RES) 19-21. Recently, biohybrid cloakings have been investigated to improve
the colloidal stability, prolong the circulation time in the bloodstream, and
reduce the interactions with the RES 22-24. Furthermore, biohybrid moieties
derived from cancer cell membranes constitute an innovative source for the
delivery and presentation of antigens 25,26.
This  thesis  work  began  with  a  study  on  the  formulability  of  PSi  NPs
characterized by different surface properties and surface charges with cell
membrane-derived moieties. The biohybrid nanosystems were then evaluated
in terms of improved colloidal stability in human plasma and
cytocompatibility in multiple cells. Then, the contribution of the cell
membrane wrapping to the cellular uptake of hydrophilic, negatively charged
NPs was assessed in the presence of uptake inhibitors, in order to determine
the mechanisms employed by naked and coated NPs to enter the cells. Taking
into consideration the immunostimulatory properties of PSi NPs, a multistage
cancer nanovaccine was prepared by glass capillary microfluidic
nanoprecipitation of an acetalated dextran polymeric layer encapsulating PSi,
followed by the coating with a cancer cell membrane. The immunological
profile of this system was determined in vitro, analysing the expression of co-
stimulatory signals and the secretion of cytokines. The therapeutic efficacy of
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the nanovaccine was then evaluated in murine melanoma models as a
monotherapy and in combination with immune checkpoint inhibitors. Finally,
the composition of the adjuvant core was changed into an oncolytic
adenovirus and the novel nanoplatform, named ExtraCRAd, was assessed for
viral infectivity, the pathway followed by ExtraCRAd or naked virus in cellular
uptake, and preventive and therapeutic efficacy as a monotherapy in vivo in
different lung adenocarcinoma and melanoma models.
Literature overview
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2 Literature overview
2.1 Immunotherapy and Its Actors
The immune system was considered, for a long time, just the body’s
army against foreign pathogens, preventing diseases caused by bacteria,
viruses, and parasites 27-29. However, in recent years, the role of the immune
system has shifted to include other categories of pathologies. Chronic
inflammation and activation of the immune cells of the central nervous system
(microglia, astrocytes, and in part, oligodendrocytes) have been associated
with development of Alzheimer’s disease and other forms of dementia,
Parkinson’s disease, lateral amyotrophic sclerosis and other
neurodegenerative diseases 30-33. Moreover, immune cells and their soluble
mediators play a role in hypertension and cardiovascular diseases, where they
are involved in the tissue repairing and remodeling phases 34-36. A correlation
has been established between alterations in the relationship between
microbiota and immune system and inflammation-caused metabolic chronic
diseases (e.g., obesity and insulin resistance) 37,38. Sometimes, the immune
system itself can cause pathologies, by losing control over the small
autoreactive population of cells normally present in the body, overreacting
against the body itself, and leading to autoimmune diseases 39. Finally, a
complex relationship has been proved between tumors and the immune
system 40.
Immunotherapy is the exploitation of the patient’s immune system to
treat a disease. Active immunotherapy includes treatments aimed to prime an
immune response against antigens (e.g., vaccination and tolerogenic
vaccination), while passive immunotherapy is performed by administration of
antibodies or adoptively transferred T cells 15,41. An immunomodulation can
be achieved also by the administration of cytokines or immunosuppressant
drugs 42. These therapeutic options interface with different actors playing a
role in the immune system. The traditional role of the immune system is
mediated by two arms, the innate and adaptive systems 29. The innate immune
system includes cells presenting germline-encoded receptors not subject to
rearranging: antigen presenting cells, eosinophils, mast cells, neutrophils, and
natural killer (NK) cells, as depicted in Figure 1 43.
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Figure 1. Schematic of the cells and immune mediators belonging to
the innate or adaptive immune response. Adapted and reproduced with
permission from 44; copyright © Elsevier B.V. 2017.
These cells use pattern recognition receptors (PRR) to identify pathogen
associated molecular patterns, highly conserved features in bacteria and
viruses 45,46. The same receptors are also sensitive to danger associated signals
(damage-associated molecular pattern, DAMPs) released from necrotic cells
(e.g., heat-shock proteins, uric acid, and high-mobility group box 1 protein) 47.
The PRR receptors identified so far are Toll-like receptors (TLR), C-type lectin
receptors, nucleotide-binding oligomerization domain (NOD)-like receptors,
inflammasome, retinoic acid inducible gene-I, and absent in melanoma 2
(AIM2)-like receptors 45,46. These receptors are positioned on the extracellular
membrane, in the endosomal compartments, and in the cytoplasm 48-51. The
receptor mediates the activation of innate cells either into effector cells that
eliminate the pathogen, or in the case of antigen presenting cells (APCs), they
mature and prime cells of the adaptive arm 43. The adaptive immune response
is constituted by lymphocytes, T and B cells, whose receptors recognize the
antigens presented by the APCs 52. The traditionally proposed mechanism of
APCs-mediated activation of naïve T cells focuses on 3 signals: (1) antigen
presentation on the major histocompatibility complex (MHC; class I for
cytosolic or cross presented antigens, class II for endosomal and extracellular
ones); (2) presentation of co-stimulatory signals (e.g., cluster of
differentiation CD80); and (3) secretion of proinflammatory cytokines 53.
Naïve T cell can differentiate into CD4 helper T cells, CD8 cytotoxic
lymphocytes, and regulatory T cells based on the position of the antigen and
the state of activation of the APCs 54-57. However, recently the type of PRR
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activation has been shown to influence the downstream differentiation of the
lymphocytes 57. B cells can be activated by the presence of B cell receptor
(BCR)-specific antigens, co-stimulation provided by T-helper cells (CD40),
together with a specific cytokine environment, leading to the production of
specific antibodies isotypes. However, these cells can also be activated T cell-
independently, by a combination of signals provided by TLRs and antigens on
BCRs, leading to the production of immunoglobulin M 52.
These players represent the target for cancer immunotherapy and
nanotechnology in particular, as discussed in the next section.
Cancer immunotherapy is based on the theory that the interaction
between the tumor and immune cells is a three stage immunoediting process,
as shown in Figure 2.
Figure 2. Cancer immunoediting as a three stage process: a cancer
tissue presents danger signals and tumor antigens, which are recognized by a
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variety of immune cells in the elimination phase. This phase can evolve into a
dynamic equilibrium, which is eventually broken, with changes in the tumor
microenvironment promoting the tumor growth. Reproduced with
permission from 58; copyright © 2011, American Association for the
Advancement of Science.
The first phase, elimination, involves cells of the immune system
scavenging the body for mutated cells and killing them. In the second stage,
cancer cells that fortuitously escaped from the first stage start growing and
organizing into a tumor; however, this growth is controlled in a dynamic
equilibrium by the immune system. Finally in the third phase, tumor escape,
due to the array of mutations acquired and the selective clonal antigen
downregulation caused by the immune system, the tumor growth is
uncontrolled 59. Thereby, several therapeutic options aim to restore the
balance between immune cells and tumor (second phase), or in the best cases
to result in eradication of all the cancer cells (first phase).
Monoclonal antibodies interfering with the mechanisms of regulation of
the immune system (immune checkpoint inhibitors, ICI) currently represent
the gold standard in the treatment of hot tumors (cancer tissues characterized
by a high infiltration of immune cells) 2,60. However, the therapeutic efficacy
of ICI is limited in patients with cold tumors 3. Cancer nanovaccines and
oncolytic viral vaccines constitute promising platforms for the priming of a
cancer-specific immune response, to be supported by the following
administration of ICIs, in cold tumors 61-65.
2.2 Nanotechnology for Cancer Immunotherapy
Nanotechnology has played a role in biomedical applications since the
first investigations on liposomes and polymeric nanosystems 66,67.  NPs  owe
their popularity to the advantages they bring when compared to conventional
drug formulations 68,69. In particular, nanosized systems can modify the
dissolution rate of poorly water-soluble compounds, increasing their efficacy
and allowing a reduction in the dose, or rekindle the research into potent small
drug molecules discarded into the discovery process because of their
suboptimal physicochemical properties for their formulation 70,71. Moreover,
the delivery of a therapeutic compound with NPs modifies the
pharmacokinetics of the drug, resulting in different sites of accumulation,
lower or less dangerous side effects (e.g., the delivery of doxorubicin —DOX—
into liposomal platforms reduces dose-dependent cardiotoxicity, but induces
palmar-plantar erythrodysesthesia) 72-74. Nanosized drug delivery systems
constitute versatile platforms for the simultaneous delivery of multiple drugs
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(also with different physicochemical properties), of drugs and RNAs (with
different targets and kinetics for the release), and of drugs and imaging
moieties (theranostic particles allowing the simultaneous treatment and
diagnosis)75-80. In spite of all the abovementioned advantages, targeted NPs
struggle to reach the tissue of interest: e.g., a meta-analysis of the data
reported in literature revealed that, on an average, only 0.7% of the injected
dose of particles reaches the tumor in animal models 81. Moreover, upon
administration, the foreign platforms become cloaked by tissue-specific
proteins, leading to the formation of a protein corona 19,82. The modification
of the particles’ surface is patient-specific and the formation of a protein
corona may have undesired effects on the performance of the NP (e.g., loss of
efficacy of targeting moieties, undesired flagging by the complement,
unspecific uptake by immune cells, immunotoxicity). These factors lead to
differences in the pharmacokinetics and interfere with the particles uptake by
the target cells 20,83-86. Thereby, the engineering of NPs needs further
development, in concert with deeper research into the interactions between
such NPs and the human body 87.
Nevertheless, NPs serve as exquisite tools in immunotherapy, both for
immunostimulation and immunosuppression 7,88,89. Different parameters
influence the interactions between the immune system and NPs, as
summarized in Figure 3 and in Table I.
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Figure 3. NPs parameters influencing the interaction with the immune
system. A careful development of the NPs precisely tailors the effect of the
biomaterial on the immune cells. Reproduced with permission from 90,
copyright © 2019, Elsevier B.V.
The size of a nanoplatform influences its distribution and draining to the
lymph nodes, together with the type of immune response induced, whether it
is an antibody or a cell-mediated one 91-93. The shape exerts an effect mainly
due to the effect on the cellular uptake; particles presenting different aspect-
ratio (AR), from spherical to filaments, are characterized by different uptake
efficiencies 94-96. The surface charge of a NP is responsible for enhanced
interaction with the cell membrane, leading to increased uptake 97. In addition,
a surface presenting different charges will interact with different proteins,
ultimately presenting a different protein corona 98,99. Moreover, other
properties of the NPs impacting the interaction with immune cells are the
surface chemistry (mainly the hydrophobicity of the system) and the elastic
module of the particle. An increase in the hydrophobicity of the surface
increases the immunogenicity of the particle due to the danger signal
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delivered to the dendritic cells (DCs), together with the delivery of
complement fragments that adsorb non-specifically to the particles’ surface
11,86,100-102. As for the elasticity/rigidity, rigid particles are internalized faster by
APCs, resulting in increased activation of the cell 103-105. Finally, the loading of
adjuvants in the particles increases the immunogenicity of the formulation,
while the position of the antigen on the particles influences both the
immunogenicity and type of immune response 106.
Table I. Parameters influencing the immunogenicity of NPs.
Parameter NPs Effect In Vitro In Vivo Ref
Size Polypropylen
sulfide spheres
Size-
dependent
translocation
to lymph
nodes
- Interstitial injection of
fluorescent NPs. 20 nm
NPs faster lymphatic
drainage; 20 and 40 nm
NPs longer residence
time in lymph node
107
Lecithin/glyce
ryl
monostearate
oil-in-water
emulsions
Size
dependent
adjuvant effect
- Subcutaneous injection
of smaller NPs (230 nm)
induced higher antibody
titer and cellular
activation
108
Carboxylated
polystyrene
spheres
Size
dependent
immune
activation
- 40 nm particles induced
higher titer of
antibodies, together with
higher priming of CD4
and CD8 T cells
91
Silica NPs Size
dependent
enhanced
cross
presentation
70 and 100
nm particles
enhanced the
antigen cross
presentation
- 109
Shape Polystyrene
particles
modified to
obtain
different AR
Shape
dependent
uptake by
APCs
Elongated
particles
adhere more
than spheres,
but they are
less uptaken
- 94
Mesoporous
silica rods
with different
AR
Shape
dependent
biodistributio
n
- Spherical particles are
retained in the liver,
while long rods are
sequestrated in the
spleen
110,111
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Table I. Cont.
Parameters NPs Effect In vitro In Vivo Ref
Shape
Polystyrene
particles
modified to
obtain
different AR
Shape dependent
activation of APCs
APCs are
activated by
spherical
particles more
than by
elongated ones
- 112
Spherical or
rod-like
particles
Shape dependent
type of immune
activation
-
Spherical
particles
induced
Th1-
mediated
response,
while rod
particles
promoted
Th2-
mediated
activation
95
Surface Charge
Hyaluronic
acid-modified
chitosan NPs
Charge dependent
composition of the
protein corona
Hyaluronic
acid-modified
NPs bind anti-
inflammatory
proteins and do
not bind
clusterin
- 113
Gold NPs with
different
surface
modifications
and charges
Charge dependent
biodistribution of the
NPs
-
Neutral
charged
particles
interact
the most
with
immune
cells
(Kupffer
cells in
liver, white
and
marginal
pulp in
spleen)
114
Hydrophobicity
Gold NPs with
different
hydrophobicity
Hydrophobicity
dependent
immunostimulation
Higher
hydrophobicity
leads to higher
cytokine  and
immune
stimulation
- 115
PSi NPs with
different
surface
chemistry
Surface chemistry
dependent
immmunostimulation
Increased
presentation of
co-stimulatory
signals and T
cell
proliferation
- 11
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Table I. cont.
Parameters NPs Effect In Vitro In Vivo Ref
Elasticity/Rigidity
PEG-based
nano
hydrogels
Flexibility
dependent
biodistribution
Softer particles
have reduced
uptake by
macrophages
Softer
particles have
prolonged
blood
circulation
116
Rigid
liposomes
Flexibility
dependent
activation of
APCs
-
Intramuscular
injection
resulted in
increased
activation of
APCs and
increased
priming of
naïve T cells
117
Position of the
Antigen
PLGA NPs
Antigen position
on activation of
the immune
system
-
Enhanced
production of
antibodies
and memory
cells for the
formulation
with antigen
encapsulated
and adsorbed
90
APCs, antigen presenting cells; AR, aspect:ratio; DCs, dendritic cells;
NPs, nanoparticles; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic
acid); PSi, porous silicon.
The new wave of interest in research about cancer immunotherapy
culminated in the choice of immunotherapy as the breakthrough of the year
in 2013 by Science, resulting into a shift from the development of NPs for the
delivery of chemotherapeutics to nanosystems for immunotherapy 1. Cancer
immunotherapy focuses on three main approaches to modify the immune
balance in the tumor microenvironment (TME) and to restore the functional
tumor-specific T cells: (1) adoptive T cells therapy, with cells primed ex vivo;
(2) modification of the TME, with the use of ICI; and (3) cancer vaccination
for the priming of novel tumor antigen-specific T cells 118.
Materials engineering plays a role in all the three different therapeutic
approaches, as shown in Figure 4. Biomaterials scaffolds can influence the
immune environment in vivo, by slowing down the release of modulators from
the matrix or microparticles (MPs) embedded in the scaffold; engineered
particles are used in the ex vivo manipulation of immune cells, and
nanomaterials serve also as drug delivery systems or vaccines targeted to the
lymphoid organs or to the tumor microenvironment 119-121.
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Figure 4. Different areas of research for biomaterials in cancer
immunotherapy: as delivery systems to the lymphatic organs or the tumor
microenvironment, for ex vivo engineering of the immune cells (adaptive
therapy), or as scaffolds for the in vivo recruitment, activation, and priming
of cells. Reproduced with permission from 119; copyright © 2017 WILEY-VCH
Verlag GmbH & Co. KGaA, Weinheim.
Different types of materials have been explored for the creation of
immunomodulatory niches for the activation and priming of immune cells in
vivo 122,123. In particular, polymers and inorganic mesoporous silica have been
loaded with chemoattractants (e.g., granulocyte-macrophage colony
stimulating factor, GM-CSF), adjuvants and antigens to attract and prime
APCs against the tumor 124-126. Alternatively, the priming of APCs can be
mediated by DNA and siRNA loaded into MPs incorporated into the synthetic
niche 127,128.
Micro/nanoparticles can also function as artificial APCs. For example,
in adoptive T cell therapy, cancer specific T cells are isolated from the patient
before being purified and expanded ex vivo 129. The NPs are decorated with
antigen-specific MHC together with immunostimulatory signals (e.g., CD28),
or with CD3 and loaded with interleukin (IL)-2, to bind with T cells and
stimulate them 130,131. In this application, the shape of the system is
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fundamental. For example, non-spherical particles are more effective in the
proliferation of the lymphocytes 132.
The two main areas of investigation for the role of NPs in cancer
immunotherapy concern the delivery of therapeutics to the tumor
microenvironment and their use as cancer vaccines 118. Traditional nanosized
delivery systems for chemotherapeutics have been repurposed to interfere
with the TME, by acting on the vasculature and the remodeling of the immune
cells 133,134. The TME contains immunsuppressive cells like M2 macrophages
and myeloid-derived suppressor cells (MDSC); such cells can be repolarized
to proinflammatory, anti-tumoral ones or directly depleted, to allow for the
action of anti-tumoral T cells 135. The administration of TLR agonists by NPs
repolarizes the macrophages to M1 136, while different nanoformulations have
been investigated for the delivery of bisphosphonates, RNAi, cytokines and
growth factors to facilitate the repolarization or killing of the M2 population
137-140. Finally, the co-administration of traditional chemotherapeutics induces
immunogenic cell death, with the release of DAMPs and tumor antigens. The
simultaneous loading of chemotherapeutics and immunostimulating
molecules into a single particle allows the exploitation of the antigens released
by the dying cells as vaccines 134,141,142.
Nanovaccines have been developed according to two different
approaches (Figure 5): (1) NPs can serve as a delivery system for antigens
and adjuvants, targeted to the lymph node and to specific types of APCs, and
(2) the biomaterials constituting the NPs can act as adjuvants, delivering the
antigens to APCs 143. Polymeric MPs and NPs have been prepared for the
loading and delivery of model cancer antigens (usually melanoma-associated
model antigens like chicken ovalbumin, OVA, or tyrosinase related protein 2,
TRP-2) and a variety of TLR-agonists and other adjuvants 144,145. The
treatment with these formulations induced antigen-specific immune response,
with  the  priming  of  CD8  T  cells 146-149. Other nanoplatforms like micelles,
liposomes, gold NPs, protein NPs, can efficiently deliver antigens and
adjuvants, and promote an immune response 150-157.
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Figure 5. Strategies for the development of cancer vaccines. a)
nanovaccines for the co-delivery of antigens and adjuvants; b) immunogenic
nanoplatforms for the delivery of antigens; c) immunogenic nanoplatforms
inducing immunogenic cell death of cancer cells; and d) NPs delivery
adjuvants and chemotherapeutic agents to induce immunogenic cell death.
Reproduced with permission from143; copyright © 2018 WILEY-VCH Verlag
GmbH & Co. KGaA, Weinheim.
Furthermore, nanovaccines may have intrinsic adjuvant properties due
to the biomaterial itself, which induces activation of PRRs (e.g., by polymers
activating TLRs or stimulator of interferon genes, STING) 158-163. The
immunostimulative properties of the NPs have been associated with different
mechanisms, as detailed in Table I. In the case of polymeric NPs, increasing
the molecular weight of polymers increases their immunogenicity 10, while
higher degradation rates are correlated with the activation of APCs 9.
Nanovaccines assembled from or containing pH-responsive polymers enable
the endosomal escape of the loaded antigens, while the rupture of the
endosome delivers an activation signal to the APCs 158,164,165. Alternatively, cues
from nature (specifically viral structures) are recognized by APCs as pathogen-
associated molecular patterns (PAMPs), leading to immunostimulation, and
have been exploited as cancer vaccines.166 Nanovaccine platforms have also
been evaluated in combination with ICI to achieve a “prime and boost” effect
163,167,168. However, NPs developed according to the traditional perspective as
carriers for antigens and adjuvants may result in the induction of an
unbalanced immune response in the clonal selection of cells not presenting
the antigen, resulting in an inefficient antigen presentation 3,15,143. Thereby,
alternative sources of antigens and core adjuvant nanoplatforms are currently
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being developed and are discussed in the following sections, starting from the
development of biohybrid coatings as an innovative source of antigens for the
investigation of novel materials like PSi and for the re-evaluation of oncolytic
viruses as natural vaccine adjuvants.
2.3 Biohybrid Nanosystems–Cell Membrane
Some of the most critical limitations of the abovementioned
nanosystems are limited circulation time and interactions with the cells of the
immune system. To solve these challenges and taking inspiration from nature,
two different approaches have been proposed so far: (1) the bottom-up one
focuses on the functionalization of nanomaterials with biological stealth
molecules (e.g., surface functionalization with CD47 markers that transmit a
“do-not-eat-me” signal to macrophages and other cells of the RES 169,170, hitch-
hiking particles onto cells 171-174); and (2) a top-down approach aiming to
decorate the surface of micro/nano-carriers with moieties derived from the
cell membrane, resulting in the development of biohybrid systems carrying all
the advantages of biological camouflage 21. Alternatively, NPs can be directly
bound to the surface of cells (e.g., by red blood cells, RBCs) to increase their
circulation time in the bloodstream 171,175.
To date, several different sources of membranes have been explored to
coat different types of micro/nano-platforms with different type of
applications, from drug delivery to artificial intracellular bioreactors, as
shown in Figure 6 and listed in Table II 21,176.
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Figure 6. Summary of the different cells used as sources of cell
membranes and examples of the cores coated so far. Modified and
reproduced with permission from 21; copyright © 2018 WILEY-VCH
Verlag GmbH & Co. KGaA, Weinheim.
The membrane of RBCs is regarded as an optimal biocamouflage source
due to the prolonged circulation of such cells, with limited interactions and
uptake by the RES 177-180. The prolonged circulation time leads to enhanced
accumulation into tumor or inflamed tissues by passive accumulation due to
enhanced permeability and retention effect 181-186. Moreover, RBCs can be
collected in high amounts from the patient or acquired from blood donors,
with good possibility for a blood type standardized formulation for scale-up
21,171. The attractive feature of prolonged circulation is particularly sought after
in the case of drug delivery systems 21. Moreover, the coating with membrane
moieties is useful also to improve the biocompatibility and circulation time of
imaging and photothermal probes. A further use of RBC membrane-coated
nanoplatform is for immune modulation, both for cancer immunotherapy and
as a vaccine against viral pathogens 187-189. Concerning these applications,
RBCs membranes need a further modification with the introduction of
targeting moieties or antigens by lipid insertion, to allow for a targeting to the
tissue of interest or for the priming of an antigen-specific immune response
190. Finally, RBC-nanosponges have been developed to detect new viral
antigens and remove hemolytic animal and bacterial toxins, small toxic
molecules (e.g., pesticides) or to adsorb excessive chemotherapeutic drugs,
and as a decoy target for anti-RBC antibodies in autoimmune hemolytic
anemia 191-195.
Platelets have recently gained prominence as membrane sources due to
their wide availability, and their natural targeting to the sites of inflammation
(in wounds, cancer, and vasculature) 196,197. The applications of these platforms
range from drug and growth factor delivery for the treatment of infections,
cancer, restenosis, and wound healing, to photothermal cancer therapy and
detoxification of autoantibodies 21,198,199.
The development of platforms coated with the cell membrane of
immune cells exploits the intrinsic targeting of such cells to the sites of
inflammation (e.g., cancer and autoimmune diseases like rheumatoid arthritis)
200-202. Leuko-like vectors represent the first examples of biohybrid PSi
platforms coated with macrophage cell membrane for targeting of inflamed
endothelium 203. Other core particles (mainly polymeric, mesoporous silica,
liposomes, iron oxide, gold nanoshells and upconversion particles) were
evaluated for drug delivery of chemotherapeutics, for photothermal therapy,
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for detoxification from bacterial toxins in sepsis, and for antibody-based
detection of circulating cancer cells 204-209.
The rationale behind the investigation of platforms cloaked with a cell
membrane derived from stem cells is the striking resemblance between stem
cells and cancer cells, in particular for the ability of stems cells to target the
tumors 210,211. Stem cells are also employed towards organ regeneration 212.
Finally, a clever approach to induce immunity against bacterial infection
is to coat the NPs with membrane fragments derived from the outer
membrane of bacteria 213.
Table II. Examples of biohybrid platforms presented according to the source
of cell membrane.
Type of
Membrane
Type of Core Particle Application Drug /
Imaging Agent
Ref
RBC
Gold NPs and nanocages
Iron oxide NPs
Upconversion NPs
Bismuth NPs
Melanin NPs
Perfluorocarbon-loaded
HSA NPs/PLGA NPs
Prolonged
circulation,
photothermal
therapy,
photoacoustic
therapy,
photodynamic
therapy, ROS
generation, MRI
contrast agents
/
23,181,182,184,214-
219
PLGA NPs
Prolonged
circulation
Targeting
peptides inserted
in cell
membrane
DOX
22,190,220
PLA NPs
PLGA NPs
Delivery of
chemotherapeutic
and prolonged
circulation
DOX 24,183
PLGA NPs
Targeted delivery of
chemotherapeutic,
prolonged
circulation
PTX 221
PLGA NPs
PEG nanohydrogels
Gold nanowire motors
Nanosponge for
toxins,
autoantibodies,
small molecules
purification
/
191,192,194,222-
226
PLGA NPs
Bacterial antigens
inserted in the
membrane
vaccination
/ 188,226
PLGA NPs
Tumor antigens
cancer vaccine
/ 189
Iron oxide-loaded PLGA
NPs
Detection of viral
pathogens
/ 195,227
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Table II. Cont.
Type of
Membrane
Type of Core Particle Application
Drug /
Imaging
Agent
Ref
RBC
Chitosan magnetically
guided NPs
Prolonged circulation
DOX/PTX/Iron
Oxide
228
PCL core coated with
thermosensitive polymer
and cell membrane
functionalized with dye
Prolonged circulation, on-
demand release
PTX 229
Silica core coated with a
layer of titanium oxide
Prolonged circulation, on
demand release
DTX 230
Poly(L-?-
glutamylcarbocistein) NPs
Chitosan-based nanogels
Prolonged circulation, pH-
dependent release
PTX
PTX/IL-2
231,23
2
Gelatin NPs
nanogels
Prolonged circulation,
detoxification
Vancomycin
233,23
4
Intrabody NPs
Prolonged circulation,
intracellular delivery
Intrabodies
(anti-human
telomerase
reverse
transcriptase)
235
Ace-DEX NPs
Glucose-sensitive delivery
of insulin, prolonged
circulation
Insulin, glucose
oxidase,
catalase
236
Cholesterol-
reinforced
RBC
Remote loading, prolonged
circulation, pH-dependent
release
DOX 237
Platelets
PLGA NPs
Binding to inflamed
tissues, binding to infected
tissues
DOX/vancomyc
in
238
Decoys for autoantibodies / 239
Nanogels Enhanced tumor targeting DOX/TRAIL 238
Silica NPs
Targeting to circulating
tumor cells
TRAIL 240
Polymeric NPs
Sequential targeting to
bone and myeloma
Bortezomib,
tPA
241
WBC PSi MPs
Avoiding immune
clearance, prolonged
circulation, transport
through inflamed
endothelium, enhanced
accumulation in tumor
DOX 203
Iron oxide magnetic
nanoclusters
Binding to circulating
cancer cell, enrichment of
circulating cancer cells
/ 208
Monocytes/
Macrophage
s/Neutrophi
les
PLGA NPs, mesoporous
silica NPs, liposomes
Enhanced stability in
serum, increased uptake in
tumor cells, prolonged
circulation, augmented
accumulation in tumor,
targeting and treatment of
metastases
DOX,
emtansine,
carfilzomib
204,20
5,242,
243
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Table II. Cont.
Type of
Membrane
Type of Core Particle Application
Drug /
Imaging
Agent
Ref
Macrophages Gold NPs, upconversion
NPs
Prolonged circulation,
enhanced uptake,
increased photothermal
activity
/ 206,244
PLGA NPs
Detoxification from
endotoxins
/ 207
Neutrophils PLGA NPs
Targeting to the inflamed
joints, reduction of the
inflammation
/ 245
Bacteria-
activated
Macrophages
Gold/silver nanocages
Prolonged circulation,
retention at the site of
infection, irradiation-
dependent antibacteric
effect
/ 246
T Cells PLGA NPs
Avoiding immune
clearance, improved
efficacy together with low
dose irradiation
PTX 247
Stem Cells
Gelatin nanogels
Enhanced in vitro efficacy,
higher accumulation in the
tumor
DOX 248
PLGA MPs and NPs
Stem-cell mimicking,
preservation of cardiac
functions, similar effect to
cardiac stem cells,
retention in site of
ischemia
Cardiac stem
cells medium
(with GF),
VEGF
212,249
Iron oxide NPs,
upconversion NPs
Enhanced stability in
physiological fluids,
magnetic hyperthermia
applications,
photodynamic therapy
/ 250,251
Endothelial
Cells
Various NPs
Cell-mediated
encapsulation in the
membrane, MRI, magnetic
hyperthermia
/ 252
? Cells Electrospun nanofibers
Proliferation of ? cells
cultured over the scaffold,
maturation of the cells
/ 253
Hybrid
Membranes
RBC+Platelets, PLGA NPs
Prolonged circulation,
detoxification, targeting to
atherosclerotic plaque
/ 254
Platelets+WBC, magnetic
beads
Isolation and enrichment
of circulating tumor cells
/ 255
Leutosomes
(WBC+cancer cell),
liposomal NPs
Prolonged circulation,
enhancement of dose
delivered to tumor
PTX 256
Mesenchymal stem
cell+RBC, PLGA NPs
Cell proliferation in vitro,
targeting to liver,
attenuation of acute liver
toxicity
/ 257
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Table II. Cont.
Type of
Membrane
Type of Core
Particle
Application Drug/Imaging
agent
Ref
Bacterial
Outer Vesicles
Gold NPs
Enhanced
stability in
physiological
buffer, increased
priming of APCs
/ 213
Ace-DEX, acetal-functionalized dextran; APCs, antigen presenting cells; DOX,
doxorubicin; DTX, docetaxel; GF, growth factor; HAS, human serum albumin;
IL-2, interleukin 2; MPs, microparticles; MRI, magnetic resonance imaging;
NPs, nanoparticles; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic
acid); PTX, paclitaxel; RBC, red blood cell; tPA, tissue plasminogen activator;
TRAIL, TNF-related apoptosis-inducing ligand; VEGF, vascular endothelial
GF; WBC, white blood cell.
2.3.1 Cancer Cell Membrane Coated Platforms
In the treatment of cancer, and particularly in the case of metastatic
stage, it is of paramount importance to be able to deliver the therapeutic agent
at the site of action. Coating nanosized drug delivery systems or theranostics
with membranes derived from cancer cells increases the targeting efficiency
of the system due to a homotypic effect demonstrated in several experiments
with different source cells 26,258-262. Thereby, the coating with cancer cell
membrane conjugates leads to enhanced stability of the nanosystems in
biological environment and to targeting and preferred uptake in the target
tissue 263-267. Moreover, the membranes of cancer cells are rich in tumor
antigens or neoantigens, allowing for more effective cancer vaccines 26,167,268,269.
Such vaccines will prime the immune system towards a wider range of
antigens compared to traditional NPs carrying only a limited amount of
known antigens 25,270. This will prevent the mechanisms of immune evasion
adapted by the cancer cells by downregulating the antigen presentation on the
MHC 271,272.
In the first proof of concept, Fang et al. demonstrated the maturation of
APCs after incubation with polymeric NPs loaded with an adjuvant and coated
with a cell membrane derived from cancer cells 26. The APCs activated by this
nanoplatform primed T cells, with the secretion of interferon (IFN)-? and in
vitro T cell-mediated killing assay 26. The following in vivo evaluation was
performed on murine melanoma models swapping the core particle from
PLGA to CpG adjuvant NPs 25. The prophylactic vaccination with the NPs
induced a multi-antigen immune response, which effectively prevented the
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tumor growth when the animals were rechallenged 25. Moreover, biohybrid
nanovaccines represent the ideal priming phase in prime and boost immune
therapeutic schemes, with the subsequent administration of ICI to support
and potentiate the immune response elicited by the vaccine 273-276. Kroll et al.
evaluated the therapeutic efficacy of this combination therapy in a poorly
immunogenic melanoma model, increasing the number of animals with
prolonged survival when compared to the monotherapy with ICI 25.
In conclusion, the use of cell membranes derived from cancer cells
represents an innovative and attractive technique to deliver multiple antigens,
while improving the total stability of the system.
2.4 Porous Silicon (PSi)
During the last decades, innovative materials have been explored as
potential NPs for drug delivery, including PSi. This material was initially
reported by the Uhlirs 277, but the first to theorize possible biomedical
applications of the porous substrate, given its biocompatibility and
biodegradability, was Professor Leigh Canham in 1995 278.  Usually,  PSi  is
produced by anodization of a silicon wafer in an ethanolic fluoridic acid
solution, followed by micronization, milling, or high-pressure
homogenization to MPs or NPs 279-283. Alternatively, microfabrication
techniques can produce PSi MPs with discoidal shape or microneedles 284-286,
or bottom-up processes can lead to the production of microcrystalline PSi NPs
with homogenous size distribution between 3 and 20 nm 287. PSi was firstly
investigated due to its photoluminescent properties, which render it a suitable
platform for biosensors and for theranostics 288,289.
Additionally, this material is very versatile for the type of chemistry that
can be introduced on the surface 13. The surface of “as-anodized” particles
(hydrides) is not stable to oxidative processes from the atmospheric O2;
moreover, this reactivity may interfere and degrade payloads and is
fundamental in the formation of reactive oxygen species (ROS), decreasing the
biocompatibility of the material 290-292. Different surface modifications have
been proposed to stabilize the surface, and one of the most commonly
employed is the thermal oxidation of the particles, which occurs from
temperatures higher than 400°C and is complete (full removal of hydrides) for
temperatures higher than 600°C with the introduction of O2 atoms  on  the
surface and in the Si backbone 293,294. Salonen et al. developed the thermal
carbonization and hydrocarbonization processes, allowing the transformation
of the hydride groups into hydrocarbon and carbons 295-298. After regeneration
of the surface with hydrofluoric acid, silanolic groups form on the external
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layer for further functionalization with acidic and basic moieties, and then
with coating, imaging, and targeting moieties 299.
Other advantages of PSi NPs for drug delivery applications include
tunable pore size with large pore volume, and high surface area 13, enabling
also a control over the degradation speed to orthosilicic acid in biological
conditions 300-303. Amongst the factors controlling the degradation rate,
surface functionalization has a prominent role and a common surface
functionalization to enhance the circulation time, PEGylation has shown a
dramatic increase in the degradation time of PSi particles with the extension
of the PEG chain 304. Moreover, the degradation of PSi particles is dependent
on the concentration of ROS, where the particles in tissues presenting higher
ROS levels (e.g., tumors) exhibited faster degradation compared to particles
in healthy tissues 305.
The high pore volume and surface area allow a high loading degree for
drugs, biologics or second-stage nanovectors 284,306,307. However, one of the
downsides of PSi concerns the control over the release of the payload, where
the conformation of the large pores cannot prevent the leakage of the drug,
inducing premature release 13. This problem spurred the search for possible
solutions from surface modifications to different physical entrapment
techniques 13. Payloads can be entrapped within the pores after loading by
sealing of the pores. The sealing happens after the oxidation process or by
formation of a silicate shell by reaction between the degradation product of
PSi and reagents in solution 308-310. Moreover, polymers can be chemically
conjugated on the surface of the particles, effectively preventing the
premature release of the drug 311. Amongst the physical entrapment methods,
PSi NPs were encapsulated into polymeric or lipidic matrix by conventional
emulsion 312-314, by microfluidics 315-318, by aerosol flow reactor 319,  and  by
biopolymers and thermosensitive polymers adsorbed onto the PSi particles’
surface 320-322.
PSi particles have been developed and evaluated for the diagnosis,
treatment, and theranostics in different pathologies. For example, PSi
composites were investigated as drug delivery systems in cancer, in
cardiovascular diseases, and in the treatment of metabolic disorders (mainly
diabetes) 13,323,324.
PSi vectors have also been extensively investigated in cancer therapy.
For example, NPs have been modified with targeting ligands and encapsulated
into pH-sensitive matrices to produce a punctual drug delivery at the site of
interest 316,325-334. As for bigger particles, discoidal MPs constitute the first
stage in a multistadius vector, and are designed to marginate in the blood
vessels, allowing a more intimate contact with the endothelial cells for an
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easier delivery of the second stage into the cancer tissue 306,335-339. Recently,
PSi was investigated as a platform for the delivery of small molecules to treat
the injury in myocardial infarction 333,340,341. PSi MPs and NPs serve as optimal
carriers for oral delivery of small molecules 307, to improve their dissolution
rate and bioavailability, and of insulin and other therapeutic peptides like
GLP-1 342-344. PSi NPs were also investigated for the delivery of growth factors
analogues to the brain 345.  Finally,  PSi  NPs  have  also  applications  for  the
treatment of acute liver failure 346.
2.4.1 Immunological Profile of PSi
Like other engineered biomaterials, PSi interacts with the immune
system. In particular, the silicon nanostructured surfaces increase the total
level of cytokines secreted by the peripheral blood mononuclear cells (PBMC),
without significant differences when compared to standard polystyrene 347.
However, when PSi is processed into MPs and NPs, it exhibits surface
dependent activation of APCs. The highest levels of immunostimulation are
achieved by particles with hydrophobic surfaces (thermally hydrocarbonized
PSi, THCPSi) or by fast-degrading hydrophilic particles (Figure 7) 11.
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Figure 7. PSi surface-mediated activation of APCs. a) Percentage of
immature monocyte derived dendritic cells (imDC) expressing CD80 after
incubation with the particles; b) percentage of imDC expressing CD86; c)
percentage of imDC expressing CD83; and d) percentage of imDC
presenting human leucocyte antigen DR isotype (HLA-DR). Reproduced
with permission from 11; copyright © 2014 Elsevier B.V.
The high immunogenicity of THCPSi can be explained by the adsorption
of protein fragments and by the activation of DAMP, while for the hydrophilic
particles, the rapid degradation leads to the production of (ortho)silicic acid,
an immunostimulant molecule, and to the precipitation of silica crystals with
the activation of DAMPs 11,348. In the case of PSi MPs, the immunostimulatory
effect is mainly mediated by the activation of IFN-type I genes in a MyD88
and STING independent way. This leads to an increase in the production of
IFN-? and regulated upon activation, normal T cell expressed, and secreted
(RANTES) 349. Moreover, PSi MP-mediated delivery of antigens to APCs
enhances the cross presentation, probably due to an early localization in the
early endosomes, followed by a translocation to the endoplasmic reticulum 349.
PSi MPs surfaces are suitable for further modification with other adjuvants.
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For example, lipopolysaccharide (LPS) and monophosphoryl lipid A (MPL)
were successfully adsorbed on the particles’ surface, and promoted
inflammasome-mediated activation of the APCs, enhancing the secretion of
IL-1?, IL-6 and TNF-? 350. The mature APCs activate CD8 T cells with
increased secretion of IFN-?. Finally, the treatment with adjuvant-adsorbed
MPs enhanced the efficacy of a combinatory therapy with liposomal
doxorubicin 351.
PSi has also been applied in particle-mediated antibody dependent cell
cytotoxicity (ADCC) and in immunostimulant antibodies 13. The binding of
CD40 monoclonal antibody increased the activation of B cells when compared
to the antibody in solution 352. PSi particles can also be loaded with
chemotherapeutic drugs and targeted via monoclonal antibody to CD326,
promoting ADCC and immunostimulation with the secretion of IL-12 by T
cells 353.
Thereby, given its immunologically attractive properties, PSi constitutes
an attractive choice as the core material in a cancer nanovaccines.
2.5 Oncolytic Viruses (Adenovirus)
The interest toward the use of pathogenic viruses as a treatment for
tumors was sparked already in the 1950’s, by observations of spontaneous
regression of established tumors concomitantly with or after a viral infection
354. These treatments, despite the initial reduction in the tumor, did not
present long term efficacy and were associated with possible severe side effects,
due to the inoculation of pathogenic viruses (e.g., West Nile virus), thus they
were dismissed in favour of the more promising chemotherapy 354. The return
of viruses for therapeutic use started with their molecular biology
modification into transfection vectors for gene therapy 355. Moreover, the
elucidation of the pathways of interferon mediated signalling pointed to the
lack or diminished activity of viral defences in tumoral cells, making oncolytic
viruses (OVs) an ideal agent for cancer therapy 356,357. The first OV, Imlygic (T-
Vec), was approved in 2015 by the Food and Drug Administration and the
European Medicinal Agency for the treatment of melanoma 358,359.
The mechanisms of action of oncolytic viruses are multiple and diverse
6. The traditionally proposed action is based on selective lysis in cells defective
for interferon and apoptosis pathways 360. Lately, a second mode of action for
OVs has been investigated, as shown in Figure 8. OVs in their cell lytic action
serve also as cancer vaccines, inducing the release of tumor associated
antigens and neoantigens together with DAMPs, while acting themselves as
adjuvants 361. The viral nucleic acid present in an infected cancer cell
phagocytized by APCs activates TLR, inducing the maturation of the APCs 362.
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Moreover, studies on viral vectors for gene transfer revealed an immunogenic
role of the capsid with the activation of proinflammatory pathways in different
cell types 355. The immunological action of OVs in the tumor
microenvironment transforms immunologically cold tumors into hot tumors,
with a synergistic effect when combined with immune checkpoint inhibitors
363,364. OVs can also modify and disrupt tumor vasculature by targeting to the
vascular endothelial growth factor (VEGF) 365-367.
Figure 8. Comparison between the mode of action of a) traditional
cancer immunotherapy and b) oncolytic viral therapy in the tumor
microenvironment; c) OVs act also as vaccines, priming distal lymph
nodes and turning the tumor microenvironment less immunosuppressive.
Reproduced with permission from 368; copyright © 2014 Macmillan
Publishers Limited.
The OVs designed so far have been engineered for intratumoral local
administration to maximize the lytic effect. However, given the variability
among solid tumors, the not always easy access to lesions, and the presence of
metastases, intravenous (i.v.) administration of the viruses is currently being
investigated 369,370. One major obstacle is represented by neutralizing the
antibodies and pre-existing immunity to the specific OVs, which cause the
inactivation of the majority of the virus administered i.v.6. Possible solutions
include the use of different serotypes, the coating and cloaking of the virus
with PEG and other polymers, or a vaccination scheme with the priming phase
with OVs and the boost phase mediated by a completely different virus 360,371-
375. The modifications sought in the development of OVs aim to achieve
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enhanced targeting to cancer cells, attenuating the pathogenicity, increase the
antitumor immunity, control and limit the effect of the antiviral immune
response, and improve the bioavailability 360. Moreover, the approval of an OV
in the clinic requires also the establishment of procedures to obtain clinical-
scale and -grade production of the viral vector, suitable purification complying
with the requirements set by regulatory authorities and an online quality
control system 376.
Adenovirus is an attractive candidate for oncolytic viral therapy, because it is
easily produced with high titer into immortalized cell lines with protocols for
the purification, either by centrifugation with cesium chloride gradients or by
chromatographic methods, which are widely available 376. Moreover, its
genome is easy to modify with deletions of early genes, which usually prevent
viral spreading, and the insertion of transgenes with the engineering of
conditionally replicating adenoviruses (CRAd) 360. In particular, two widely
described modifications involve a 24 base pairs deletion in the gene coding for
EA1, allowing the viral replication only in cells defective in the Rb mechanism
(i.e., cancer cells) and the insertion of genes coding for immunostimulatory
factors (e.g., GM-CSF) 354. Human adenoviruses are present in roughly 50
different serotypes, all characterized by linear double stranded DNA, enclosed
within a non-enveloped icosahedric capsid, as shown in Figure 9 377.
Figure 9. Structure of a human adenovirus, showing the fibers,
hexons and pentons. The average size of the core is 90 nm. Reproduced
with permission from 378; copyright © 2010, American Association for the
Advancement of Science.
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There are three types of proteins forming the capsid: (1) hexons, with a
structural role; (2) pentons, for the secondary binding to ?v?3,5 integrins for
internalization; and (3) fibers for the interaction and recognition with
coxsackie and adenovirus receptor (CAR) 377,379,380. The therapeutic efficacy of
this virus is partially mined by the diffuse pre-existing immunity and by the
need of the CAR receptor on the target cells to promote viral internalization.
In an effort to address these issues, less common or hybrid, chimeric,
serotypes have been developed, together with engineering of the fibers to
modify biodistribution, reactions with the neutralizing antibodies, and
interactions with and internalization into the tumor cells 379,380.
One first generation oncolytic adenovirus is currently approved in China,
in combinatorial treatments with chemotherapeutics in the treatment of head
and neck cancer 381. Other viruses, encoding for the expression of
immunostimulatory cytokines are in clinical trials 354,382. Moreover, CRAd
modified to increase the CpG adjuvant sequences was coated with antigenic
peptides with the formulation of a complete cancer vaccine, PeptiCRAd 383.
The vaccine is easily assembled by simply mixing the oncolytic adenovirus
with peptides modified to increase their positive charge, where by electrostatic
interaction the antigens adsorb on the surface of the capsid, tilting the balance
between the relative viral and anti-tumoral immune response. Recently, a
similar modification was developed also for an enveloped virus like vaccinia,
resulting in a complete vaccine platform delivering tumor-specific antigens 63.
Thereby, adenoviruses can be considered as biological NPs, exhibiting a
complexity still not achievable with synthetic NPs, which provide
immunostimulatory cues to APCs, serving de facto as adjuvant cores for
cancer nanovaccines.
2.6 Glass Capillary Microfluidics and Nanoprecipitation
Microfluidics is the technique involving fluids at the micro/nano-scale
for analytical and synthetic purposes 384-386. However, one of the major
applications of microfluidics resides in the preparation of MPs and NPs 387-390.
This technique presents several advantages when compared to the bulk
preparation methods. For example, given the size of the channels, small
volumes of reagents are needed, which is important in the case of expensive
reagents/drugs, and at the same time, obtaining libraries of particles with
different properties 391,392. Moreover, the high degree of control over the
process parameters leads to the production of homogenous micro/nano-
systems, characterized by high drug loading degree 393. The most important
feature of microfluidics is the possibility to achieve a laminar flow in the
channel, defined by the following parameters, such as the Reynold number (a
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dimensional number indicating the ratio between inertial to viscous forces in
the channel), capillary number (ratio between the viscous forces and the
surface tensions between the liquids), and the flow ratio (indicating the ratio
between the flow rate of the different phases) 391,394. Other advantages of
microfluidics are the short diffusion distance between the molecules in the
fluids, enhancing the mixing efficiency and reducing the mixing time, as well
as the possibility to continuously produce the particles 395. Furthermore, the
yield of production can be as high as 700 g of particles per day, with an easy
scaling-up mediated by the connection in series or parallel of multiple chips
396. Microfluidics platforms are designed and produced by a variety of
materials (e.g., polydimethylsiloxane, glass capillaries, and polycarbonate) 391.
Glass capillary microfluidics provides the possibility to use organic
solvents without compromising the integrity of the chip, and they are quite
robust platforms, durable, with a wide range of channel geometries, as shown
in Figure 10 391,393,396,397.
Figure 10. Configurations achievable in microfluidics platforms for
the preparation of micro- and nano-drug delivery systems. a, b, d ,e, and f
are the geometries available in glass capillary microfluidics. Reprinted with
permission from 396; copyright © 2017, The Royal Society of Chemistry.
MPs are usually obtained through droplet-based microfluidics,
employing geometries shown in Figure 10 (a, d, e, and f). The emulsion
droplets generated present homogenous dimension, high encapsulation
efficiency, and the possibility to co-encapsulate different drugs 391. MPs
produced by single and double emulsion have been investigated in the delivery
of chemotherapeutics for colon cancer and oral delivery of model drugs, and
proteins 315,317,329,398-403.
NPs can be successfully produced by nanoprecipitation from two
miscible solvents in a 3D-hydrodynamic focused geometry 396. The fast mixing
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time inside the fluidics channel is smaller than the nucleation time for the
polymer, thereby both the nucleation and nuclei growth occur in the same
conditions, resulting in NPs with homogenous size 393,404. NPs with different
applications, ranging from delivery of chemotherapeutics in cancer to
receptor-mediated oral delivery of insulin and analogues have been
engineered by microfluidics nanoprecipitation in glass capillaries 316,318,342.
Lately, ultra-high loading degree particles are being investigated to increase
the drug delivery efficiency 405.
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3 Aims of the study
The main goal of this thesis was to develop nanovaccines made of a
biohybrid nanosystem containing inorganic nanoparticles or OVs cloaked into
cancer cell membranes for cancer immunotherapy applications.
More specifically, the aims of the present work were:
 To evaluate the influence of PSi nanoparticles’ surface chemistry on
the membrane extrusion process, on the stability in biologically
relevant media, and on the cytocompatibility in different cells.
 To investigate the effect of the cell membrane source and coating, on
the uptake of hydrophilic, negatively-charged particles in different cell
lines.
 To develop a multistage biohybrid system as a nanovaccine for cancer
immunotherapy and evaluating the immunological profile of the
system in vitro.
 To assess the in vivo therapeutic efficacy of the nanoplatform in two
murine melanoma models and assay the potential of a combination
therapy with immune check-point inhibitors.
 To explore the translatability of the cancer cell membranes coating to
OVs both in vitro and in murine tumor models, checking the masking
effect of the cell membrane towards neutralizing antibodies, as well as
the efficiency and immunostimulation of the biohybrid nanovaccine as
preventive and therapeutic treatment.
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4 Experimental
The methods employed in the experiments of the studies described in
this thesis are presented in this section. The details of the methods herein
described can be found in the original publications (I-V). The PSi
nanomaterials employed in some of the works here presented (publications I,
II, III, and IV) were fabricated by the collaborators at the Laboratory of
Industrial Physics, Department of Physics and Astronomy, University of
Turku, Finland. The in vivo work presented in publication IV and the work
presented in publication V have been performed in collaboration with the
ImmunoViroTherapy Lab, Drug Research Program, Division of
Pharmaceutical Biosciences, University of Helsinki, Finland.
4.1 Materials (I-V)
The detailed description of the materials employed in this thesis can be
found from the materials and methods sections of original publications I-V.
4.2 Methods
4.2.1 Cell Membrane Extraction and Membrane Extrusion Technique
The following protocol applies to all the cell lines employed as a source
of cell membrane (I-V). The concentration of a cell suspension was
determined and the cells were then washed 3 times with cold phosphate buffer
saline (PBS; 1X). The pellet of the cells was resuspended in lysing buffer (20
mM of TrisHCl pH 7.5, 10 mM of KCl, 2 mM of MgCl2, all from Sigma Aldrich,
USA; 1 mini tablet of proteases inhibitors/10 mL, Thermo Fisher, USA; Milli-
Q water), and the separation of the cell membranes was performed by
ultracentrifugation, as previously described26. The lysing buffer was then
discarded and replaced with the medium chosen for the extrusion process (see
details in the materials and methods section of the original publications I-V).
The final systems were produced through a membrane extrusion,
adopting an extruder (Avanti Polar Lipids, USA) and polycarbonate
membranes (pore sizes reported in publications I-V, Whatman, UK). The
samples and cell membrane vesicles were suspended into the buffer of choice
and passed through the extruder 21 times, before being collected into a new
Eppendorf for the following studies.
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4.2.2 Nanoparticles Production
4.2.2.1 PSi Nanoparticles
The PSi forming the core of the systems described in this thesis has been
prepared as follows: silicon wafers (p+ -type, 100 and resistivity of 0.01-0.02
? cm) were anodized into aqueous hydrofluoric acid (38%):EtOH (1:1)
solution by applying electrical current (50 mA/cm2)301. The porous layer was
detached by the wafer substrate through a rapid increase in the current to the
region used for electropolishing322. Generally, free-standing films were first
modified, then reduced to nanoparticles by wet milling and the particles were
separated into different size fractions by centrifugation318. The particles were
then washed and stored in 99.5% of EtOH.
In the works presented herein, we employed particles with different
surface modifications for further studies. The list of the type of modification,
abbreviation, chemicals used in the modification, procedure and resulting size
and surface charge of the batches employed is presented in Table III,
alongside with references describing the preparation methods in detail.13
Table III. Surface modification of the PSi NPs employed in publications I-IV.
Surface
Modification
Abb
r Chemical Procedure
Size
[nm
]
Surface
Charge
[mV]
Ref
Thermally
Carbonized
TCP
Si
Acetylene
Performed on THCPSi films.
Additional 10 min of acetylene
flow (1 L/min), followed by
annealing for 10 min, under N2
flow, at 820°C. The films were
then cooled back to RT under
N2 flow.
159,
8
-26,5 406
3-
aminopropylt
riethoxysilane
TCPSi
APT
S-
TCP
Si
3-
aminopropyl
triethoxysila
ne-toluene
solution
(10%)
Performed on TCPSi films.
Immersion in HF, followed by
immersion in APTS-toluene
solution. The medium
employed in the wet milling is
5% APTS-toluene solution
187.
0
+35.1
299,31
8
Undecylenic
acid-modified
thermally
hydrocarboni
zed
UnT
HCP
Si
Acetylene,
followed by
undecylenic
acid
Exposure of the films to a flow
of N2 (1L/min) for the O2 and
moisture removal. Thermal
hydrocarbonization in a flow
1:1 of N2:acetylene for 15 min
at 500°C, followed by cooling
to room temperature under N2
flow. Undecylenic
modification: dipping films
into acid solution for 16 h at
120°C.
140.
5
-21.9
407,40
8
Thermally
Oxidized
TOP
Si
-
Thermal oxidation at 300°C
for 2 h with ambient air
179.
5
-23.7 409
HF, hydrofluoric acid; N2, nitrogen; O2, oxygen; RT, room temperature.
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4.2.2.2 Synthesis of Acetalated Dextran (AcDEX) (III-IV)
The detailed protocol for the synthesis of AcDEX polymer has been
reported in the literature 318. Briefly, dextran (1 g, MW 9 000-11 000 kDa,
Sigma Aldrich, USA) was put into a two-neck round bottom flask, previously
dried, and purged with N2. About 10 mL of dimethyl sulfoxide (DMSO, Sigma
Aldrich, USA) were employed to dissolve dextran. Then, 15.6 mg of
pyridinium-ptoluenesulfate (Sigma Aldrich, USA) and 3.4 mL of 2-
methoxypropene (Sigma Aldrich, USA) were added to the flask. The reaction
was performed for 1 h, before being quenched with trimethylamine (1 mL,
Sigma Aldrich, USA). The obtained polymer was precipitated in water (200
mL)  and  washed  twice  with  0.01%  v/v  trimethylamine  solution  (pH  8.0),
yielding acetalated dextran.
4.2.2.3 Glass Capillary Microfluidics and Nanoprecipitation (III-IV)
Co-flow microfluidics configuration was employed in the
nanoprecipitation fabrication of the NPs presented in the original publications
III and IV. The microchip in publication III was assembled, as previously
described, using borosilicate glass capillaries mounted on a glass slide316. The
inner capillary (580 μm and 1000 μm, internal and external diameter, World
Precision Instruments, USA) was tapered to ca. 20 μm in a pipette puller (P-
97, Sutter Instruments Co, USA) before being carefully sanded to a diameter
of approximately 80 μm. This capillary was inserted and coaxially aligned
within a bigger capillary (internal diameter 1000 μm). The capillaries and the
connections were sealed, where needed, with transparent epoxy resin (5 min
Epoxy, Devcon). The microchip was connected with polyethylene tubes
attached to syringes controlled by automatic injection pumps (PHD 2000,
Harvard Apparatus, USA). The microchip employed in the original
publication IV was modified from the literature and the two capillaries were
assembled within the structure for an easier setup of the system410.
The NPs were prepared by nanoprecipitation in glass capillary
microfluidics device. In detail, a solution of the polymers (10 mg/mL) in 95%
of EtOH was prepared and used to resuspend 1 mg of TOPSi NPs. A layer of
AcDEX was deposited on the surface of TOPSi particles, encapsulating them.
The parameters chosen for the encapsulation were inner solution (particles
and polymer), at a flow rate of 2 mL/h and the outer solution (polyvinyl
alcohol, 1% w/v, Sigma Aldrich, USA), at a flow rate of 40 mL/h. The
preparation procedure of the final system is described in detail in the
experimental section of the original publications III and IV.
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4.2.3 ExtraCRAd (V)
The OVs constituting the core of ExtraCRAd were prepared in the
facilities of the IVT Lab, according to standard protocols described
elsewhere383,411,412. Briefly, the viruses employed in publication V were:
Ad5?24, developed by creating a 24 base-pair deletion (?24) in the E1A gene
to allow for the replication only in cancer cells with mutated Rb/p16 pathway;
Ad5?24-CpG is an OVs (24 bp deletion) equipped with a CpG-enriched
genome in the E3 gene; Adeno5-luc is an adenovirus carrying a luciferase
transgene.
The viruses were selected by colony formation and propagated in A549
cells or HEK 293 cells before being purified using cesium chloride gradients.
The viral particle concentration was determined by analyzing the optical
density at 260 nm, while the standard infectivity assay (ICC) on A549 were
performed to determine the infectious titer.
All the viruses produced were aliquoted and kept at -80°C in A195 buffer
(10  mM  of  Trizma  Base,  75  mM  of  NaCl,  5%  (w/v)  Sucrose,  0.02%  w/v  of
Tween 80, 1 mM of MgCl2, 100 μM of EDTA, 0.5 % of EtOH 99.5%, and 10
mM of L-hystidine) until further use.
4.2.4 Physicochemical Characterization (I-V)
All the biohybrid systems presented in this thesis have been extensively
characterized.
4.2.4.1 Dynamic and Electrophoretic Light Scattering (DLS and ELS)
DLS and ELS were employed to determine the hydrodynamic diameter
(Z-average), the polydispersity index, and the surface charge of the developed
nanosystems (I-V), using a Zetasizer Nano ZS instrument (Malvern Ltd, UK).
The measurements were performed either in Milli-Q water, 5.4% of glucose,
0.9% of NaCl physiological solution or PBS (1X). Further details on the
dispersing media can be found from the original publications.
4.2.4.2 Stability Studies in Physiologically Relevant Media
The behavior of the nanosystems in biological conditions in the case of
i.v. administration was tested by assessing the stability of the systems in fresh
frozen plasma (FFP; provided by Finnish Red Cross), for up to 2 h. FFP was
filtered with a 0.2 ?m filter (0.2 ?m sterile Acrodisc® Syringe Filters with
Supor® Membrane, Pall Corporation, USA) before use. About 300 ?L of each
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sample were pipetted in 1.5 mL of physiological relevant media and stirred at
200 rpm and 37 °C. Aliquots were taken at different times during the
incubation period and analyzed by DLS and ELS.
4.2.4.3 Transmission Electron Microscopy (TEM, I-IV) and Cryo-TEM (V)
The morphology of the nanosystems (I-IV) was investigated by TEM.
About 5 μL of sample were deposited on carbon-coated copper grids, followed
by overnight drying. The particles were imaged with a Jeol JEM 1400 (Jeol
Ltd, Japan) microscope. ExtraCRAd samples from publication V were imaged
by  cryo-TEM  on  a  JEOL  JEM-3200FSC  microscope.  Briefly,  about  3 L of
fresh samples were applied to carbon-coated copper grids that were
immediately dropped into liquid nitrogen to snap freeze the samples.
4.2.4.4 Scanning Electron Microscopy (SEM, I) with Energy Dispersive X
Rays and High Resolution Scanning Electron Microscope (HR-SEM,
III)
The surface and elemental composition of the biohybrid nanosystems
presented in publication I were analyzed by EDX (Oxford INCA 350, Oxford
Instruments, UK) connected with an SEM (Hitachi S-4800, Hitachi, Japan)
at 30.0 KeV. The samples were applied to carbon-coated copper grids.
In publication III, the surface of the nanosystems was imaged with HR-
SEM. Briefly, 10 ?L of the samples (1 mg/mL) were deposited on fragments of
wafers of silicon and dried overnight in open air. The samples were then
imaged with a Zeiss Ultra-55 scanning electron microscope (Zeiss, Germany).
4.2.4.5 Light Microscopy (II, III)
An inverted confocal microscope (Leica, TCS SP5 II HCS-A, Leica,
Germany) was employed to image cells seeded in Lab-TekTM 8 chambers slides
to evaluate the intracellular uptake of fluorescently labelled NPs in publication
II. A fluorescent microscope (Leica DM6000, Leica, Germany) was adopted
to image the nanosystems developed in publication III to confirm the
successful conjugation of Trp-2 antigen (FITC-conjugated) onto
TOPSi@SpAcDEX particles and further support the presence of the cell
membrane on the surface of TOPSi@AcDEX@CCM. TOPSi particles were
loaded with tetramethylrhodamine (TRITC, Sigma Aldrich, USA), while the
cell membrane was stained with Cell Mask® Deep Red (Thermo Fisher, USA),
and the nuclei were stained with DAPI.
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4.2.5 In Vitro Evaluation of Biohybrid Systems
4.2.5.1 Continuous Cell Lines and Isolation of Peripheral Blood Monocytes
The following cell lines were utilized in the studies herein presented:
human lung carcinoma (A549, American Type Culture Collection (ATCC)®
CCL-185TM), murine skin melanoma cells (B16F10, ATCC® CRL 6475™),
murine skin melanoma cells transfected with ovalbumin (B16.OVA, kindly
provided by Prof Richard Vile, Mayo Clinic, Rochester, USA), human B cells
with dendritic cell morphology (BDCM, ATCC® CRL2740™), human
endothelial somatic hybrids (EA.hy926, ATCC® CRL 2922™), primary human
derma fibroblasts (kindly provided by Dr. Jackson, Mitochondrial Medicine
group, University of Helsinki, Finland), human embryonic kidney cells (HEK
293, ATCC® CRL-1573™), human liver carcinoma (HepG2, ATCC® HB-
8065™), murine dendritic cells (JAWS II, ATCC® CRL-11904™), human
macrophages (KG-1, ATCC® CCL-246™), human breast adenocarcinoma cells
(MCF-7, ATCC® HTB-22™), epithelial metastatic breast cancer cells (MDA-
MB-231, ATCC® HTB-26™), human metastatic prostate cancer cells (PC-3,
ATCC® CRL-1435™), human ovarian carcinoma cells (SK-OV-3, ATCC® HTB-
77™).  BDCM  and  KG-1  cells  were  kindly  provided  by  the  Institute  for
Molecular Medicine Finland. All the other cells, when not otherwise specified,
were bought from ATCC® (USA).
A549 and SK-OV-3 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM), low glucose, supplemented with 10% heat inactivated fetal
bovine serum (FBS), 1% of penicillin streptomycin (PEST), 1% of L-glutamine,
1% of non-essential amino acids. HEK 293, MCF-7 and PC-3 cells were
cultured in  10% of  FBS in  DMEM high glucose.  EA-hy926,  fibroblasts,  and
HepG2 were cultured in 10% of FBS in DMEM high glucose supplemented
with 1% of sodium pyruvate. B16F10 and BDCM cells were cultured in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented with 10% of FBS,
1% of PEST, 1% of L-glutamine, and 1% of NEAA. B16.OVA were cultured in
10% of FBS in RPMI, with the supplement of 10% of geneticin (G418, Thermo
Fisher, USA) to select the OVA positive cells. KG-1 macrophages were cultured
in Iscove’s Modified Dulbecco’s Medium (IMDM), supplemented with 10% of
FBS, 1% of PEST, 1% of L-glutamine, and 1% of NEAA. Finally, JAWS II cells
were cultured in 20% of FBS in ?-Minimum Essential Medium (MEM)
supplemented with 5 ng/mL of murine GM-CSF.
PBMCs  (III) were isolated from human blood of anonymous blood
donors, received by the Finnish Red Cross. PBMCs were obtained from the
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whole blood after lysing the erythrocytes with ammonium-chloride-potassium
lysing buffer for 5 min, followed by centrifugation and washing with cold PBS.
The cells were then cultured in 10% of FBS in RPMI for further use.
All the cells were maintained in an incubator (16 BB gas, Heraeus
Instruments GmbH, Germany) at 37°C, 5% CO2 and 95% relative humidity.
4.2.5.2 Cytocompatibility (I-IV)
The biocompatibility of the nanosystems presented in publications I-IV
was assessed in several cell lines, both human and murine, by quantifying the
adenosine triphosphate (ATP) activity to minimize the interference given by
PSi to the assay.301 Adherent cells (A549, EA.hy926, fibroblasts, HEK-293,
HepG2, MCF-7, MDA-MB-231, and PC-3) were seeded at a concentration of
10 000 cells per well in 96-well plates and left attaching overnight before
removing the medium and applying the relevant samples. After incubation,
the samples were removed and the wells were washed with (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) Hank’s balanced salt solution
(HEPES-HBSS, pH 7.4). Finally, a 1:1 HEPES-HBSS: Cell Titer Glo (Promega,
USA) solution was added to each well, the plate was shaken for 2 min and
incubated for 15 min before reading the luminescence on a Varioskan Lux
(Thermo Fisher, USA) instrument. As for non-adherent cells (BDCM, KG-1,
JAWS II, and PBMC), cells were seeded at a concentration of 10 000 cells/well
in  50  μL,  followed  by  the  addition  of  50  μL  of  the  appropriate  samples,  at
double concentration. After incubation, 100 μL of Cell Titer Glo® were added
to each well, the plate shaken for 2 min, incubated for 15 min and the
luminescence read with Varioskan Lux.
4.2.5.3 Immunological Analyses (I, III, and IV)
The immunological profile of the developed nanosystems was evaluated
by quantifying the expression of CD80 and CD86 by antigen presenting cells
stimulated with the systems. BDCM, JAWS II, KG-1, and PBMC were seeded
at a concentration of 280 000 cells per well in 12-well plates. Then, the
samples, at double the concentration were added to the corresponding wells
in the 12-well plate wells and the cells incubated for 48 and 72 h. The samples
were removed by centrifugation and the cells were incubated with monoclonal
antibodies against CD80 and 86 (mouse anti-human CD80-phycoerythrin
(PE), mouse anti-human CD86 allophycocyanin, hamster anti-mouse CD80-
allophycocyanin, all from BD (BD Biosciences, USA); rat anti-mouse CD86
peridinin chlorophyll protein (PerCP)-Cy 5.5, Biolegends, USA) in the dark at
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4 °C. The samples were then washed twice with PBS (1X) and analyzed with
the LSR II or Accurí (BD biosciences, USA) flow cytometer (FCM). As for
JAWS II cells, the adherent population was detached from the wells with cold
PBS-EDTA buffer solution.
The secretion of cytokines was evaluated by enzyme-linked
immunosorbent assay (ELISA) assays, as specified in publication III.
4.2.5.4 Uptake Studies (II, V)
The uptake pathway of biohybrid nanosystems was evaluated by
utilizing selective uptake inhibitors. In particular, the assessment conditions
are reported in the materials and methods of the original publication II. The
cells were preincubated either on ice or with the inhibitor of the uptake for 30
min before adding the samples in order to inhibit the specific pathway of cell
uptake. The cell uptake kinetic of naked or membrane-coated fluorescently-
labelled PSi NPs was evaluated over 1 and 3 h time points by FCM and confocal
microscopy.
As for FCM, the cells were seeded in 12-well plates, pretreated with the
inhibitors of the uptake, incubated with the particles, and detached by the
wells by cold PBS-EDTA buffer solution. The cells were then analyzed by FCM,
evaluating the fraction of particles adsorbed and internalized by fluorescence
quenching with trypan blue (0.005%).
Confocal microscopy was utilized for the qualitative imaging of the
particles uptake. The cells were seeded in 8-well chambers (LabTekTM) and
preconditioned with the inhibitors of the cell uptake. Then, the samples were
added to the wells and the cells were incubated for 1 or 3 h before staining and
fixation.
The cell uptake kinetics of ExtraCRAd was compared to a naked virus
over 1, 2, and 3 h by analyzing the luminescence of A549 cells infected with
virus carrying luciferase gene. After the incubation period, the wells were
washed and the cells were incubated in 5% DMEM for 24 h to allow the
expression of the luciferase. Then, the cells were lysed and the luminescence
was read in Varioskan.
4.2.5.5 Infectivity Assay (V)
The infectivity was assessed by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) using
the CellTiter® 96 Aqueus One Solution Cell Proliferation Assay (Promega,
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USA) on A549 and SK-OV-3 cells, at different viral concentrations. The
infectivity was evaluated after 3 days of incubation.
4.2.5.6 Neutralizing Antibody Assay (V)
This assay was employed to investigate the ability of ExtraCRAd to
shield the virus from neutralizing antibodies. Firstly, ExtraCRAd was assessed
against antibodies derived from the serum of immunized mice, then to rule
out the interference of other proteins, against monoclonal anti-adeno5
antibody. The serum of the immunized mice was incubated at 56 °C for 90 min
to eliminate the complement, and stored at 20°C until further use. Briefly,
A549 cells were seeded at a density of 10 000 cells per well in 50 μL of DMEM
without FBS and left attaching overnight. Then, the serum was diluted from
1:1 to 1:16384 on 1:4n scale with DMEM without FBS. The luc virus was diluted
in 0% DMEM up to  a  concentration of  3.03×109 viral particles per mL and
added to the serum dilutions or to the monoclonal antibody (4×106 viral
particles,vp, for each sample). The samples were then incubated at room
temperature for 30 min on a shaker. Finally, 50 μL of each sample were
pipetted over the cells into each well. The cells were incubated for 1 h at 37 °C
before  adding  150  μL  of  10%  of  DMEM  to  each  well  and  continuing  the
incubation overnight. Next, lysis of the cells and the addition of the substrate
for luciferase (Promega,USA) were performed, and analyses of the
luminescence was conducted with a Varioskan Lux instrument.
4.2.6 In Vivo Assessment of Biohybrid Cancer Vaccines (IV-V)
The nanosystems developed in this thesis were assessed in vivo, in
murine lung adenocarcinoma and melanoma models, as preventive or
therapeutic cancer vaccines.
4.2.6.1 B16.F10, B16.OVA, CMT64.OVA, and LL/2 models
The murine strain chosen for the experiments was C57BL/6J, obtained from
Scanbur (Denmark) at 4–6 weeks of age. The development of subcutaneous
tumor models was achieved by injecting either 1× 105 of B16F10, 2.5× 105 of
B16.OVA, 7× 106 CMT64.OVA,  or  1.5×  105 LL/2  tumor  cells  (when  80%
confluent in T175 flasks) on the right flank of each mouse. Details about the
treatment schedule are given in the figure legends in the original publications
IV and V. During the experiments, the tumor volume was recorded every two
days  by  using  a  digital  caliper.  Maximum  (L)  and  minimum  (l) tumor
diameters were recorded and tumor volumes were calculated according to the
formula: (L×l 2)/2.
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4.2.6.2 Ex-Vivo Immunological Analysis
Tumors and lymphoid organs were collected from the animals after
sacrifice. The tissues were smashed into single cell suspensions through
strains (70 μm mesh). The cells were preserved at 80°C until use. The
samples were pretreated with Fc-blocker for 30 min, before staining for the
immunological profile (T cells, CD8, CD4 and CD3) and dendritic cells (CD11b,
CD11c, CD86, and CD80). All the anti-mouse antibodies employed were from
BD Biosciences (BD). Gallios (Beckman Coulter) or Accuri’ (BD Biosciences,
USA) FCM was used to acquire data and FlowJo (Threestar) software was used
for data analysis.
4.2.7 Ethical Permit (IV-V)
All the experimental protocols presented in publications IV and V were
approved by the Laboratory Animal Center of the University of Helsinki and
by the National Animal Experiment Board of Finland, according to the Act
(497/2013) and the Decree (564/2013) on Animal experimentation approved
by the Finnish Ministry of Agriculture and Forestry and the EU Directive
(2010/63/EU), following the EU’s Guidelines for Accommodation and Care of
Animals.
4.2.8 Statistic Analysis
The results are presented as mean ± standard deviation (SD) or
standard error of the mean (SEM). Graphpad Prism versions 5.0 or 7.0
(Graphpad Software, San Diego, California, USA) were used to analyze the
data. The statistical analyses employed to analyse the data can be found in the
materials and methods sections of the works.
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5 Results and Discussion
Biohybrid NPs represent a recent development in the field of
nanotechnology and their potential is currently assessed in different
applications. In this thesis, cell membrane-wrapped nanosystems were
evaluated in terms of formulability, enhancement of colloidal stability in
physiological fluids, effect on the biocompatibility and on the immunological
profile of multistage nanovaccines. Finally, the innovative antigenic sources
represented by the cell membrane with either a synthetic or a viral adjuvant
cores were evaluated as preventive or therapeutic cancer vaccines in different
tumor models.
5.1 Effect of PSi Surface Chemistry in the Biohybrid System
(I)
The first step in the creation of a successful NP is the material
development 70. To ensure the translatability of a nanosystem to the clinics, it
is of paramount importance to develop NPs presenting homogenous size
distribution with a reproducible manufacturing process 393. In the case of
biohybrid nanovaccines, given the personalized nature of the treatment, the
production process needs to be evaluated and optimized for different types of
core particles and membrane types. Moreover, one characteristic sought for in
the development of NPs is their stability in biological fluids – this is of extreme
importance in i.v. injections. Thereby, the focus of this study was to evaluate
the formulation parameters for the preparation of reproducible biohybrid
nanoplatforms starting from PSi presenting different surface characteristics
and to evaluate the stability of those platforms in biological fluids.
5.1.1 Formulation of the Biohybrid NPs
In this preliminary study, three different PSi NPs, namely APTS-TCPSi,
UnTHCPSi and TCPSi, were coated with a model cell membrane derived from
a human macrophage cell line, KG-1. The PSi particles presented were
different in the surface charge (APTS-TCPSi being positively charged, while
the other two particles are negatively charged 413)  and  in  the
hydrophilicity/hydrophobicity of the surface (UnTHCPSi are hydrophobic
particles, while the other two particles are hydrophilic 11,414). The formulative
parameters assessed were the buffer used for the extrusion (Milli-Q water or
Sucrose, 0.3 M) and the influence of the tip sonication associated to the
membrane extrusion process. The results of the formulative screenings are
presented in Table IV.
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Table IV. Influence of the extrusion buffer and use of tip sonication on the
formulation  of  PSi  characterized  by  different  surface  charge  and  surface
hydrophobicity. The nanosystems obtained with different parameters are ranked
by desired values of size and zeta potential, where ++ represents the best
formulation  and  -  -  the  worst.  Reprinted  with  permission  from  publication I;
copyright © 2018, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
PSi NPs Buffers Tip
Sonication
Size [nm] PDI ?-potential
[mV]
Rank
APTS-
TCPSi
Sucrose,
0.3 M
Before Aggregated +8.8±1.3 – –
Before and
After
304±100 0.30±0.040 –6.3±1.1 ++
Milli-Q
water
Before 334±20 0.30±0.049 +31.2±0.5 +
Before and
After
Aggregated –5.7±7.1 –
UnTHCPSi Sucrose,
0.3 M
Before 575±200 0.50±0.07 –21.2±0.3 –
Before and
After
303±200 0.150±0.007 –23.7±0.2 ++
Milli-Q
water
Before 649±300 0.24±0.20 –15.1±7.1 +
Before and
after
Aggregated –8.7±0.9 – –
TCPSi Milli-Q
water
No
Sonication
410±180 0.5±0.1 –20.6±6.5 –
After Aggregated –19.8±4.9 – –
Before 246±100 0.180±0.030 –22.1±5.2 ++
Sucrose,
0.3 M
Before 289±100 0.30±0.07 –23.0±5.9 +
The extrusion of positively charged particles, as previously reported for
polymeric NPs 415, resulted in aggregates in both the extrusion buffers due to
the electrostatic interactions between the positive charges on the surface of
the particle and the negatively charged cell membranes. The use of a double
tip sonication (before and after extrusion) partially reduced the size of the
aggregates, which presented still inhomogeneous size (as highlighted by the
high polydispersity index, PDI). As for the negatively charged PSi NPs, the
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effect of the different hydrophobicity of the surface reflected into the need for
two different extrusion buffers (Milli-Q water for TCPSi and 0.3 M of sucrose
for UnTHCPSi) and for extensive tip sonication in the case of the hydrophobic
particles to achieve a stable, homogenous formulation. The successful
encapsulation of TCPSi and UnTHCPSi was confirmed also by TEM, while it
was possible to observe the aggregates formed by APTS-TCPSi partially coated
with the cell membrane (Figure 11).
Figure 11. TEM  images  of a) APTS-TCPSi, b) UnTHCPSi, and c)
TCPSi NPs extruded with cancer cell membrane derived from KG-1
macrophages. Reprinted with permission from publication I; copyright ©
2018, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Overall, biohybrid platforms constituted of negatively charged PSi NPs
presenting different surface properties were developed by adjusting the
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formulative parameters (extrusion buffer and tip sonication). However, a limit
of this technique resides in the problematic formulation of positively charged
NPs.
5.1.2 Stability in Biological Fluids
The engineering of biohybrid NPs coated with cell membrane moieties
brings along an innovative concept in the quest for stabilization of NPs in
biological fluids. Traditionally, NPs have been modified with PEG to improve
their circulation time, by decreasing the aggregation, opsonization, and
interaction with immune cells 416. However, anti-PEG antibodies have been
detected both in animal models and in humans with adverse effects on the
efficacy of repeated administrations of PEGylated NPs 417. The coating with
cell membranes provides stabilization and masking from the immune cells
(mainly by the presence of CD47, “do not eat me”, signal on the membrane) 21.
In this study, the stability of hydrophobic UnTHCPSi and hydrophilic TCPSi
NPs, as such or after coating with cell membrane, was evaluated to last in
human fresh frozen plasma up to 2 h (Figure 12).
Figure 12. Stability over time of a) UnTHCPSi and UnTHCPSi@KG-
1  or  b) TCPSi and TCPSi@KG-1 measured by size variation in DLS. The
results are presented as mean±s.d. (n=3) and were analyzed by two-way
ANOVA, followed by Bonferroni’s post-test. The levels of statistical
significance were set at *p<0.05, **p<0.01, and ***p<0.001. Reprinted
with permission from publication I; copyright © 2018, WILEY-VCH Verlag
GmbH & Co. KGaA, Weinheim.
The coating with the cell membrane partially improved the stability of
the hydrophobic NPs (Figure 12a), maintaining the size of the NPs around
500 nm, while the uncoated particles aggregated to 1 μm. In the case of the
hydrophilic TCPSi NPs (Figure 12b), they displayed a less pronounced
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stabilizing effect of the coating with cell membrane, possibly due to their
slightly higher hydrophilicity.
In conclusion, the functionalization with cell membrane moieties
improved the stability of hydrophobic particles in physiological fluids (human
plasma).
5.2 Cytocompatibility of Biohybrid Nanoplatforms (I)
Modifications of PSi NPs’ surface influence their interactions with the
cells and the mechanisms of their cytotoxicity 413. Thereby, in this set of
experiments, the effect of the surface modification with cell membrane
cytocompatibility was evaluated in a panel of primary and immortalized cell
lines representative of different human organs, by measuring the intracellular
ATP content of the cells after exposure with the NPs (Figure 13).
The cytotoxicity of the NPs was cell-type and particle-surface dependent,
as previously demonstrated 301,407. In particular, a dose-dependent toxicity for
all the NPs was present in HEK-293 and HepG2 cells, while EA.hy926 cells
were sensitive to the hydrophilic TCPSi particles, both coated and uncoated.
As for the primary human dermal fibroblasts, all the nanoplatforms were
cytocompatible in the lower range of concentrations, with both the coated
systems presenting lower compatibility at the highest concentration assessed.
In KG-1 macrophages, hydrophilic TCPSi particles, both coated and uncoated,
did not exert a toxic effect, while UnTHCPSi and UnTHCPSi@KG-1 were toxic
at the highest concentration assessed (500 μg/mL).
An excessive proliferation was noticed, mainly in EA.hy926 cells and
partially in KG-1 and HepG2 cells. This might be the result of a locally different
concentration of cells or particles amongst the wells, as indicated also by the
standard deviation amongst the different replicates. However, an
overproliferation of cells when incubated with cell membrane-coated particles
has been recorded also in immune cells (Publication III, Figure 3).
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Figure 13. Percentage of viable a) KG-1, b) human dermal
fibroblasts, c) endothelial (EA.hy926), d) renal (HEK-293), and e) hepatic
(HepG2) cells after 24 h incubation with the particles. UnTHCPSi,
UnTHCPSi@KG-1, TCPSi, and TCPSi@KG-1 were assessed at different
concentrations (0.5-500 μg/mL). Complete medium and Triton X-100 1%
represented the negative and positive controls, respectively. The data are
presented as mean±s.d. (??3) and were analyzed by two-way ANOVA,
followed by Bonferroni’s post-test, to establish comparisons and
correlation between naked and membrane-coated particles presenting the
same surface chemistry (TCPSi vs TCPSi@KG-1, UnTHCPSi vs
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UnTHCPSi@KG-1). The levels of significance were set at probabilities
**p<0.01 and ***p<0.001.
5.3 Influence of the Cell Membrane on the Uptake of PSi
NPs (II)
In this set of experiments the effect of the cell membrane coating was
evaluated on the cellular uptake in the presence of uptake inhibitors in
different cells lines to elucidate the mechanisms of action and any cell-
dependent mechanisms 418. In particular, fluorescently-labelled TOPSi NPs
were coated with cell membranes derived from A549, MDA-MB-231, MCF-7,
and PC3MM2 cell lines. The uptake was evaluated by assessing autologous
samples over each cell line quantitatively by FCM and qualitatively by confocal
microscopy.
The variations in the association and uptake of coated and naked NPs in
the presence of different uptake inhibitors are presented in Figure 14.
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Figure 14. Mechanism of cellular uptake of biohybrid NPs: Cells
(A549, A; MCF-7, M; MDA-MB-231, 231; PC3MM2, P) were incubated with
different selective inhibitors of specific uptake mechanisms (i.e., ice,
chlorpromazine, sucrose, indomethacin, nocodazol, genistein, and 3-
methyl-?-cyclodextrin) and with fluorescently modified coated and
uncoated particles for 1 and 3 h. The samples were run into FCM to
determine the fraction of particles associated before quenching the
fluorescence with trypan blue and a second running in FCM. The results
are presented as the normalized percentage of positive events recorded in
each sample divided by the percentage of a control incubated only with the
inhibitors of the uptake to allow for a comparison between different cells
and different inhibitors. The data are reported as the mean of 3 samples.
TC, TOPSi@cell membrane; T, TOPSi; A, Associated; U, Uptaken.
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The effect of the coating with the cell membrane on the uptake of
hydrophilic, negatively charged NPs was mostly connected with an increased
association with the cell membranes (TC 3A and 1A). The augmented
interaction increased the fraction of particles uptaken by the cells. As for the
mechanisms, the results suggest that the uptake of both coated and uncoated
NPs was mediated by clathrin-dependent (chlorpromazine and sucrose) and
caveolin-dependent (genistein) mechanisms, and by interactions with integer
and functional cell membranes (3-methyl-?-cyclodextrin). Furthermore, the
biohybrid NPs seemed to be less dependent on micropinocytosis (nocodazol)
compared to the TOPSi NPs alone.
In conclusion, this set of experiments suggested cell-specific differences
in the uptake of biohybrid NPs, according mainly to clathrin and caveolin-
dependent mechanisms 419.
5.4 Development and In Vitro Assessment of Biohybrid
Cancer Nanovaccine (III)
Cancer cell membrane-coated NPs have been proposed as innovative
sources of antigens in cancer vaccines, allowing the activation of the immune
system and the priming of a cancer-specific immune response 26. In this study,
the intrinsic immunostimulative properties of TOPSi NPs and of a pH-
responsive polymer (AcDEX) were combined with cancer cell membrane as
the antigenic source 11,420. The multistage nanovaccine platform was
engineered by glass capillary microfluidics, followed by membrane extrusion
to coat the cell membrane layer 318,404. The details concerning the development
of the formulation and its cytocompatibility can be found in publication III.
The immunological profile of the formulation was evaluated in
immortalized human macrophages and B cells with dendritic cell morphology
and in PBMCs. The activation profile of the cells was investigated by FCM,
analyzing the co-stimulatory markers CD80 and 86 (Figure 15a-f). The
nanovaccine core enhanced the presentation of both the activation markers in
all the cell types. The coating with the cell membrane increased the presence
of CD86 in PBMCs, while it decreased the same marker in KG-1. As for CD80,
no statistical difference was found between the naked and membrane-coated
NPs.
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Figure 15. Evaluation of the immunological profile of biohybrid NPs:
Percentage of CD86+ a) KG-1, c) BDCM, e) PBMC and percentage of CD80+
b) KG-1, d) BDCM, e) PBMC cells; g) percentage of IFN-? secreted by PBMC
incubated with the particles at 100 ?g/mL; h) IL-4 secreted by PBMC
incubated with the particles at 100 μg/mL. The results are presented as
mean±s.d. (??3). The data were analyzed by one-way ANOVA, followed by
Bonferroni’s post-test. a)-f) and h) all the samples were compared to the
control (cells incubated in medium), g) all the samples were compared to
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TOPSi@AcDEX@CCM. The levels of significance were set at *p<0.05,
**p<0.01, and ***p<0.001. Adapted and reproduced with permission from
publication III; copyright © 2016 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim
Given the importance of pro-inflammatory cytokines in the successful
priming of naïve T cells to CD8+ cells 53, the cytokine profile produced by the
stimulation of PBMCs with the nanovaccine was assessed by ELISA assay. As
shown in Figure 15g and 15h and in publication III,  the  biohybrid  NPs
promoted the secretion of IFN-?, while no secretion of IL-2 or IL-4 were
detected. This type of cytokine profile correlates with a Th-1, cell-mediated,
immune response, with the priming of CD8+ T cells and later of antigen-
specific cytotoxic T cells 11,422. Moreover, as reported in publication III, PBMCs
stimulated with the nanovaccine showed enhanced efficacy in an in vitro
killing assay against cancer cells of the same cell line as the one used for the
membranes.
In conclusion, the in vitro assessment of the immunological profile of
the nanovaccine highlighted the priming of an immunostimulatory, cell-
mediated, immune response suited for a therapeutic cancer vaccine.
5.5 In Vivo Therapeutic Efficacy of Biohybrid Nanovaccine
in Melanoma (IV)
In this work, the nanovaccine platform developed in publication III was
assessed in two melanoma models with different immunogenic profiles (one
highly immunogenic, B16.OVA, the other B16F10, low) in two therapeutic
setups, as a monotherapy and combination therapy with ICI. The therapeutic
efficacy of the monotherapy in B16.OVA model can be found in publication IV.
5.5.1 Efficacy as Monotherapy in Low Immunogenic Melanoma
In this set of experiments, the therapeutic efficacy of the biohybrid NPs
was evaluated on the control over the tumor growth and on the changes in the
immunological profile of the tumor microenvironment after two injections. As
shown in Figure 16a, the nanovaccine controls tumor growth in 44% of the
animals, in combination (Figure 16b and 16c) with an increase in the
percentage of mature, activated DCs in the tumor, and (Figure 16d and 16e)
with an augmented percentage of antigen-experienced CD8+ cells  in
comparison with the single components of the vaccine. The high aggressivity
of the tumor results in an immunosuppressive environment 422: monotherapy
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with a nanovaccine formulation can only partially control the tumor growth
163,189.
Figure 16. Biohybrid multistage NPs efficacy in B16.F10 models and
immunological profile in the tumor microenvironment: a) Single tumor
growth curves for each group. A B16.F10 melanoma model was established
in female C57BL6/J mice. The mice were treated twice, at day 6 and 13 post
tumor establishment. The groups included mock (5.4% isotonic glucose
solution), AcDEX (the adjuvant core NPs), CCM (extruded cell
membranes), and NanoCCM (cell membrane-coated TOPSi@AcDEX NPs).
The value set for the discrimination of responders to the treatment was an
absolute tumor volume lower than 300 mm3. b) Percentage of CD11c+ DCs
in the TME. c) Activation profile of DCs in the TME assessed by staining for
CD80 and 86 co-stimulatory signals. d) Percentage of CD8+ T cells in the
TME. e) Percentage of antigen-experienced tumor infiltrating lymphocytes.
The data are presented as mean±SEM. The data were analyzed with
unpaired Student’s t-test or one-way ANOVA. The levels of significance
were set at *p<0.05 and **p<0.01. Reproduced with permission from
publication IV; copyright © 2019 American Chemical Society.
5.5.2 Correlation Between Immunological Profile of the TME and
Efficacy of the Biohybrid NPs
The application of immunotherapy to the treatment of cancers misses a
link correlating how changes in the immunological profile of the TME reflect
the efficacy of a therapy 423. In this analysis, the FCM data of the TME were
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correlated with the efficacy of the treatment (divided into responders and non-
responders), as shown in Figure 17.
Figure 17. The immunological data shown in Figure 16 were
correlated with the efficacy of the treatment. Mice from all the treatment
groups were divided into responders (red) and non-responders (black
points) and the immunological profile of the TME was analyzed for changes
in a) cytotoxic T cells, b) antigen-experienced cytotoxic T cells, c) activated
and mature DCs, and d) DCs. The data were analyzed by unpaired Student’s
t-test and the levels of significance were set at *p<0.05 and **p<0.01. e)
The correlation between immunological changes in the TME and efficacy
was tested with Pearson’s correlation test (p-value is reported in each
graph). One phase exponential non-linear models were used for the data
fitting and to retrieve the R2 of each data set. Reproduced with permission
from publication IV; copyright © 2019 American Chemical Society.
A correlation was established between the small size of the tumors and
the increased presence of total and antigen-experienced T cells in the TME
(Figure 17a and 17b) and of total and activated DCs (Figure 17c and 17d).
Moreover, a fitting was obtained for an exponential model, suggesting the
interplay of multiple co-factors in the efficacy of cancer immunotherapy.
5.5.3 Therapeutic Efficacy of a Combination Therapy with ICI
Therapy with ICI has revolutionized the treatment of cancer, achieving
long term survival in subsets of patients 60. However, primary and acquired
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immune resistance hinders the global efficacy of these therapeutics 3.
Combination therapies including a priming phase mediated by cancer
vaccines, followed by a boost with ICI are currently evaluated in the clinic 4,424.
In these experiments the efficacy of a combination therapy composed of
a biohybrid nanovaccine and ICI (anti-cytotoxic T lymphocyte antigen, CTLA-
4) was evaluated in a highly immunogenic melanoma model, as shown in
Figure 18.
Figure 18. a) Single tumor growth curves for each group. A B16.OVA
melanoma model was established in female C57BL6/J mice. The mice were
treated three times, at day 6, 13, and 15 post tumor establishment. The
groups included mock (5.4% of isotonic glucose solution), aCTLA-4
(intraperitoneal injection of 100 μg of anti-CTLA-4 antibody), and
NanoCCM+aCTLA4 (cell membrane-coated TOPSi@AcDEX NPs
subcutaneously + aCTLA-4 antibody intraperitoneally). The value set for
the discrimination of responders to the treatment was an absolute tumor
volume  lower  than  400  mm3. b) Percentage of CD8+ tumor infiltrating
lymphocytes (TILs) in the TME. c) Percentage of myeloid (CD11b+) cells in
the  TME.  d)  Percentage  of  DCs  (CD11b+ and CD11c+)  in  the  TME.  e)
Percentage of activated and mature DCs, presenting CD86+ (grey), CD80+
(black), or CD86+CD80+ (red) double positive. The data are presented as
mean±SEM. The data were analyzed with unpaired Student’s t-test. The
levels of significance were set at *p<0.05 and **p<0.01. Reproduced with
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permission from publication IV; copyright © 2019 American Chemical
Society.
The combination therapy of biohybrid nanovaccine and ICI improved
the efficacy of the ICI monotherapy, as demonstrated also for oncolytic viruses
64. As presented in Figure 18a, the combination therapy controlled the tumor
growth in 87.5% of the animals, including two complete remissions, compared
to the 37.5% by the ICI monotherapy. The choice to increase the cut-off value
between responders and not responders is motivated by the differences in
immunogenicity and tumor growth rate between the two tumor models.
Furthermore, the combination treatment modified the immunological profile
of the TME, with a significant increase in the percentage of CD8+ TILs and of
DCs (Figure 18bd). The monotherapy with ICI promoted the activation of
DCs comparably to the combo treatment (Figure 18e); however, these
activated cells were not able to prime CD8+ cells.
In conclusion, the biohybrid multistage nanovaccine controlled the
growth of poorly immunogenic melanoma, modifying the immunological
profile of the TME, and increasing the infiltration of both DCs and TILs.
Moreover, combination with ICI significantly improved the efficacy of the ICI
monotherapy.
5.6 ExtraCRAd–Engineering a Biohybrid Oncolytic
Adenovirus (V)
A further step in the development and translatability of biohybrid cancer
nanovaccines concerns the modification of the core for a more adjuvant,
natural NP, oncolytic adenovirus. ExtraCRAd was engineered by a direct
application of the membrane extrusion technique, as shown in Figure 1 in
publication V. The viral NPs were then evaluated in vitro and in vivo for
differences in the oncolytic effect, shielding from neutralizing antibodies, and
for efficacy in two murine melanoma models.
5.6.1 Engineering of Viral NPs
The new system was developed after screening of the optimal extrusion
buffer (Figure 2d, publication V), identifying both Milli-Q water and PBS (1X)
as suitable buffers. The size of the viral NPs increased after extrusion by ca. 10
nm, suggesting the successful coating with the cell membrane. To confirm the
coating, naked adenovirus, cell membrane vesicles and ExtraCRAd were
imaged in Cryo-TEM (Figure 2a, publication V).
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5.6.2 ExtraCRAd Infectivity and Mode of Action
The encapsulation of an adenovirus within the cell membrane changes
the interactions between the cancer cells and the virus. As presented in
Figure 3a and 3b in publication V, ExtraCRAd displayed enhanced
infectivity towards both high and low CAR-expressing cell lines: the
incubation with ExtraCRAd resulted in enhanced oncolytic effect in A549 cells
(90% reduction in cell viability at 10 and 100 multiplicity of infection —MOI—
compared to 10% and 60% reduction achieved when the cells were incubated
with 10 and 100 MOI of naked virus, respectively). In SKOV-3 cells, incubation
with the viral NPs resulted in a 25% reduction in the cell viability, when
compared to the naked virus. Since oncolytic adenoviruses rely on the CAR
receptor to infect the cells, the difference between ExtraCRAd and naked virus
in SKOV-3 cells suggest the presence of alternative uptake mechanisms for
ExtraCRAd 381. This was confirmed by the in vivo efficacy in human lung
xenografts in nude mice (Figure 3c publication V) and by the differences in
the uptake kinetics (Figure 3d publication V), which highlighted a faster
intracellular uptake for ExtraCRAd when compared to the naked virus. The
following experiments with inhibitors of the uptake (ice, sucrose, and
chlorpromazine) suggested the presence of a clathrin-mediated,
chlorpromazine inhibited, mechanism of uptake of ExtraCRAd (Figure S6a-
c in publication V). Furthermore, the encapsulation of the virus within the cell
membrane shields the viral capsid from the neutralizing antibodies,
enhancing the fraction of virus available for infection and priming of the
immune response (Figure 3e and 3f, publication V).
5.6.3 ExtraCRAd Therapeutic Cancer Vaccine in Lung
Adenocarcinoma and Melanoma
In these sets of experiments, the efficacy of ExtraCRAd as a therapeutic
cancer vaccine was evaluated in the treatment of lung adenocarcinoma and
melanoma. In the highly immunogenic B16.OVA model, four intratumoral
injections of ExtraCRAd controlled the tumor growth in all the animals
(Figure 4a, publication V). However, in the less immunogenic and more
aggressive model B16.F10, the therapeutic vaccination with ExtraCRAd
controlled the growth only in 62.5% of the animals treated (Figure 4b,
publication V).  As  for  the  efficacy  in  a  model  of  solid  tumor,  lung
adenocarcinoma LL/2, the therapeutic vaccination of established tumors with
ExtraCRAd wrapped in homologous, tumor-matched, membrane controlled
the tumor growth in all the animals treated (Figures 4c and S7 publication
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V). These results are correlated with changes in the immunological profile of
the TME and the spleen. The vaccination with the viral NPs significantly
enhanced the percentage of antigen-specific APCs and of antigen-specific,
experienced T cells in the tumor (Figures 5 and S8, publication V). Moreover,
these changes were not limited to the TME. The intratumoral injections of
ExtraCRAd induced the priming of a systemic, antigen-specific immune
response against the tumor. Figures S9 and S10 in publication V present the
variations in the immunological profile of the spleens, while Figure S11
shows the immunological landscape in the tumor draining lymph nodes. The
animals vaccinated with the viral NPs showed enhanced percentage of DCs,
including the cross-presenting activated ones. This translated into an increase
in the percentage of CD8+ T cells and, particularly, in antigen specific CD8+ T
cells in a poorly immunogenic tumor model. These results correlate with the
ones obtained by adsorbing tumor-specific peptides on the capsid of
adenovirus 383, suggesting the potential of adenovirus as an adjuvant in cancer
vaccines and the efficacy of cancer cell membrane moieties as antigenic
sources.
5.6.4 ExtraCRAd Preventive Cancer Vaccine in Lung
Adenocarcinoma and Melanoma
ExtraCRAd’s potential in priming an adaptive and memory immune
response after a preventive vaccination scheme was evaluated in an
immunogenic lung adenocarcinoma model, CMT64.OVA and in B16.F10
melanoma model. As presented in Figure 6, publication V, the vaccination
with tumor-matched ExtraCRAd could control the tumor growth, prolonging
the overall survival in both tumor models (more than 50% of animals alive
after 40 days in CMT64.OVA cohort and after 28 days in B16.F10 cohort).
Furthermore, the efficacy of a treatment with tumor-missmatched
membranes was lower in both the tumor models. These results suggest the
presence of functional antigens on the cell membrane and the efficacy of the
viral NP in inducing an immune response in absence of any oncolytic effect 425.
In conclusion, the membrane extrusion technique was successfully
translated and applied to the field of OVs, creating a viral NP, and modifying
its mechanism(s) of entry into cells. Moreover, the coating of the virus with
elements derived from the cell membrane of cancer cells allowed for the
formulation of a powerful cancer vaccine. The treatment of established tumors
in monotherapy completely controlled the tumor growth in a highly
immunogenic melanoma model and with the majority of the animals in the
poorly immunogenic melanoma model. Moreover, this treatment controlled
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the tumor growth also in a model of solid lung adenocarcinoma. The changes
to the immunological profile of the TME were statistically significant and were
mirrored by a systemic cancer-specific immune response. Finally, a pre-
immunization with tumor-matched ExtraCRAd could control the tumor
growth, prolonging the overall survival in animal challenged with aggressive
melanoma or lung adenocarcinoma.
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6 Conclusions
Nanoparticles (NPs) have shown great promise in the treatment of
cancer and as synthetic nanovaccines. However, these systems face issues
concerning stability in physiological media, protein corona composition, and
accumulation in the target tissue. The development of biohybrid NPs can help
solve some of these challenges by employing materials shaped by evolution.
Thereby, in this thesis, the potential of biohybrid coatings of NPs was
evaluated with the aim of developing therapeutic cancer vaccines, especially
adapting the immunological properties of PSi NPs and OVs.
Firstly, the effect of surface charge and surface hydrophobicity was
evaluated in the engineering of biohybrid PSi NPs in terms of size,
homogeneity and surface charge. A positive surface charge prevented the
successful encapsulation of APTS-TCPSi within the cell membrane, while NPs
presenting hydrophobic surfaces required extensive tipsonication before and
after extrusion. Membrane-coated hydrophobic PSi NPs exhibited enhanced
stability in physiological fluids (human plasma) when compared to the naked
particles, while the higher stability of hydrophilic particles cancelled out the
contribution of the cell membrane coating. The coating with cell membrane
enhanced the biocompatibility of PSi NPs in different cells; however, surface-
dependent cytotoxicity was detected in a cell-dependent fashion.
Differences in the cellular uptake between naked and biohybrid NPs
were evaluated in different cell lines, in the presence of uptake inhibitors, to
elucidate the mechanisms of entry of the biohybrid nanosystems. The uptake
was found to be cell-specific and mainly dependent on caveolin and chlatrin
mechanisms.
A multistage biohybrid nanovaccine was developed by glass capillary
microfluidics by exploiting the immunostimulatory properties of TOPSi NPs
and the innovative antigenic source provided from the cancer cell membrane.
The nanovaccine induced the activation and maturation of human APCs in
vitro, as evaluated by the expression of co-stimulatory factors in FCM and
cytokine secretion by ELISA.
These observations led to the in vivo evaluation of the therapeutic
efficacy of the multistage NPs as cancer vaccines for melanoma. Two
subcutaneous vaccinations with the formulation controlled the tumor growth
in 44.5% of the animals, inducing significant changes in the immunological
profiles of the TME. Furthermore, changes in the immunological features of
the TME were correlated with the therapy efficacy. Next, the multistage
nanovaccine improved the monotherapy efficacy with ICI, increasing the
number of animals responding to the treatment, while inducing the priming
of a cancer-specific immune response.
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Finally, the biohybrid coating technique was translated to OVs,
obtaining viral NPs, as confirmed by imaging. The viral encapsulation altered
the uptake mechanisms of the virus, enabling enhanced infectivity also in
virus-resistant cell lines in vitro and in vivo. Moreover, the cell membrane
layer effectively shielded the virus from neutralizing antibodies. Based on
these results, further experiments demonstrated the efficacy of the viral
nanovaccine in melanoma and lung adenocarcinoma. In a highly
immunogenic melanoma model (B16.OVA) and in a solid lung
adenocarcinoma model (LL/2) the intratumoral administration of ExtraCRAd
controlled the tumor growth in all the animals, while in B16.F10 the tumors
were controlled in 66% of the animals. The vaccination with ExtraCRAd
elicited a local and systemic tumor-specific cell-mediated immune response,
as determined by the analysis of the immune contexture in the TME and in
the spleen. Moreover, the pre-immunization with ExtraCRAd wrapped in
tumor-matched membranes controlled the tumor growth and prolonged the
overall survival of tumor challenged mice.
Overall, biohybrid nanosystems and nanovaccines were developed in
this thesis by engineering PSi NPs, multistage vectors, or adenoviruses with
cell membranes derived from tumor cells for improved stability and
biocompatibility, as well as to provide an innovative antigenic source in cancer
vaccines. The publications focused on PSi NPs and oncolytic adenoviruses,
thereby not representing an exhaustive study of the formulation parameters
for biohybrid nanovaccines. The in vivo studies were focused on a highly
immunogenic tumor type (melanoma) and only partially on a solid tumor
model (lung adenocarcinoma). Further studies would extend the
generalizability and translatability of the techniques and formulations, and
would assess preventive and therapeutic efficacy of the two nanovaccine
platforms in poorly immunogenic cancer types (e.g., triple negative breast
cancer cells). A continuation of this work would also analyze the exact
composition of the isolated cell membranes, in order to evaluate which
proteins, glycoproteins, and glycans are still present after the process. Further
studies are also required to evaluate the influence of heterologous cell
membranes on the cellular uptake, together with studies evaluating
differences in the composition of the protein corona between the coated and
uncoated particles.
The exploitation of biological elements (cell membranes and viruses) as
nanosized systems takes advantage of evolution to address some of the current
issues related to NPs in cancer therapy. These systems can provide additional
features that have not been completely recreated on a lab bench, allowing also
for an increased understanding of the properties needed to improve synthetic
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particles. In the meantime, biohybrid nanovaccines can already have an effect
in the clinical treatment of cancer.
References
63
References
1 Couzin-Frankel, J. Cancer immunotherapy. Science, 1432-1433,
doi:10.1126/science.342.6165.1432 (2013).
2 Sharpe, A. H. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev
276, 5-8, doi:10.1111/imr.12531 (2017).
3 Sharma, P., et al.  Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168,
707-723, doi:10.1016/j.cell.2017.01.017 (2017).
4 Maeng, H., et al. Cancer vaccines: translation from mice to human clinical trials. Curr Opin
Immunol 51, 111-122, doi:10.1016/j.coi.2018.03.001 (2018).
5 Vilgelm, A. E., et al. Combinatorial approach to cancer immunotherapy: strength in numbers. J
Leukoc Biol 100, 275-290, doi:10.1189/jlb.5RI0116-013RR (2016).
6 Breitbach, C. J., et al. Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine 9, 31-
36, doi:10.1016/j.ebiom.2016.06.046 (2016).
7 Smith, D. M., et al.  Applications of nanotechnology for immunology. Nat Rev Immunol 13, 592-
605, doi:10.1038/nri3488 (2013).
8 Irvine, D. J., et al. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev 115,
11109-11146, doi:10.1021/acs.chemrev.5b00109 (2015).
9 Andorko, J. I., et al. Intrinsic immunogenicity of rapidly-degradable polymers evolves during
degradation. Acta Biomater 32, 24-34, doi:10.1016/j.actbio.2015.12.026 (2016).
10 Andorko, J. I., et al. Impact  of  molecular  weight  on  the  intrinsic  immunogenic  activity  of
poly(beta amino esters). J Biomed Mater Res A 105, 1219-1229, doi:10.1002/jbm.a.35970 (2017).
11 Shahbazi,  M.  A. et  al. Surface chemistry dependent immunostimulative potential of porous
silicon nanoplatforms. Biomaterials 35, 9224-9235, doi:10.1016/j.biomaterials.2014.07.050
(2014).
12 Lou, B. et al. Modular core-shell polymeric nanoparticles mimicking viral structures for
vaccination. J Control Release, doi:10.1016/j.jconrel.2018.11.006 (2018).
13 Li, W. et  al. Tailoring porous silicon for biomedical applications: from drug delivery to cancer
immunotherapy. Adv Mater 30, e1703740, doi:10.1002/adma.201703740 (2018).
14 Santos, H. et al. Mesoporous materials as controlled drug delivery formulations. J Drug Delivery
Sci Technol 21, 139-155 (2011).
15 Fontana, F., et al. Delivery  of  therapeutics  with  nanoparticles:  what's  new  in  cancer
immunotherapy? Wiley Interdiscip Rev Nanomed Nanobiotechnol 9, doi:10.1002/wnan.1421
(2017).
16 Salonen, J., et al. Mesoporous silicon in drug delivery applications. J Pharm Sci 97, 632-653,
doi:10.1002/jps.20999 (2008).
17 Santos, H. A., et al. Porous silicon nanoparticles for nanomedicine: preparation and biomedical
applications. Nanomedicine (Lond) 9, 535-554, doi:10.2217/nnm.13.223 (2014).
18 Santos, H. A., et al. Mesoporous materials and nanocrystals for enhancing the dissolution
behavior of poorly water-soluble drugs. Curr Pharm Biotechnol 14, 926-938 (2013).
19 Corbo, C. et al. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and
target drug delivery. Nanomedicine (Lond) 11, 81-100, doi:10.2217/nnm.15.188 (2016).
20 Corbo, C., et al. Personalized protein corona on nanoparticles and its clinical implications.
Biomater Sci 5, 378-387, doi:10.1039/c6bm00921b (2017).
21 Fang, R. H., et al. Cell membrane coating nanotechnology. Adv Mater 30, e1706759,
doi:10.1002/adma.201706759 (2018).
22 Hu, C.-M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic
delivery platform. Proc Natl Acad Sci U S A 108, 10980-10985 (2011).
23 Gao, W. et al. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv
Mater 25, 3549-3553, doi:10.1002/adma.201300638 (2013).
24 Aryal, S. et  al. Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug
loading and release. Nanomedicine (Lond) 8, 1271-1280, doi:10.2217/nnm.12.153 (2013).
25 Kroll, A. V. et  al. Nanoparticulate delivery of cancer cell membrane elicits multiantigenic
antitumor immunity. Adv Mater 29, doi:10.1002/adma.201703969 (2017).
26 Fang, R. H. et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug
delivery. Nano Lett 14, 2181-2188, doi:10.1021/nl500618u (2014).
27 Palm, N. W., et al. Pattern recognition receptors and control of adaptive immunity. Immunol Rev
227, 221-233, doi:10.1111/j.1600-065X.2008.00731.x (2009).
28 Kimbrell, D. A. et al. The evolution and genetics of innate immunity. Nat Rev Genet 2, 256-267,
doi:10.1038/35066006 (2001).
29 Murphy, K. et al. Janeway's immunobiology.  (Garland Science, 2016).
30 Stephenson, J., et al. Inflammation in CNS neurodegenerative diseases. Immunology 154, 204-
219 (2018).
References
64
31 Jevtic, S., et al. The role of the immune system in Alzheimer disease: Etiology and treatment.
Ageing Res Rev 40, 84-94, doi:10.1016/j.arr.2017.08.005 (2017).
32 Prinz, M. et al.  The role of peripheral immune cells in the CNS in steady state and disease. Nat
Neurosci 20, 136-144, doi:10.1038/nn.4475 (2017).
33 Fung, T. C., et al. Interactions between the microbiota, immune and nervous systems in health
and disease. Nat Neurosci 20, 145 (2017).
34 Ruparelia, N., et al. Inflammatory processes in cardiovascular disease: a route to targeted
therapies. Nat Rev Cardiol 14, 314, doi:10.1038/nrcardio.2017.33 (2017).
35 Nosalski, R., et al. Novel immune mechanisms in hypertension and cardiovascular risk. Curr
Cardiovasc Risk Rep 11, 12, doi:10.1007/s12170-017-0537-6 (2017).
36 Rodriguez-Iturbe, B., et al. Role of the immune system in hypertension. Physiol Rev 97, 1127-
1164, doi:10.1152/physrev.00031.2016 (2017).
37 Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542,
177-185, doi:10.1038/nature21363 (2017).
38 Saltiel, A. R. et al. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest
127, 1-4, doi:10.1172/JCI92035 (2017).
39 Davidson, A. et al. Autoimmune diseases. N  Engl  J  Med 345, 340-350,
doi:10.1056/NEJM200108023450506 (2001).
40 Dunn, G. P., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat
Immunol 3, 991-998, doi:10.1038/ni1102-991 (2002).
41 Kazemi, T., et al. Immunotherapeutic approaches for cancer therapy: An updated review. Artif
Cells Nanomed Biotechnol 44, 769-779, doi:10.3109/21691401.2015.1019669 (2016).
42 Ophir, E., et al. Personalized approaches to active immunotherapy in cancer. Biochim Biophys
Acta 1865, 72-82, doi:10.1016/j.bbcan.2015.07.004 (2016).
43 Janeway, C. A., Jr. et al. Innate immune recognition. Annu Rev Immunol 20, 197-216,
doi:10.1146/annurev.immunol.20.083001.084359 (2002).
44 Silva, A. L., et al. Nanoparticle impact on innate immune cell pattern-recognition receptors and
inflammasomes activation. Semin Immunol (2017).
45 Brubaker, S. W., et al. Innate immune pattern recognition: a cell biological perspective. Annu
Rev Immunol 33, 257-290, doi:10.1146/annurev-immunol-032414-112240 (2015).
46 Schaefer, L. Complexity of danger: the diverse nature of damage-associated molecular patterns.
J Biol Chem 289, 35237-35245, doi:10.1074/jbc.R114.619304 (2014).
47 Kono, H., et al. How dying cells alert the immune system to danger. Nature Reviews
Immunology 8, 279 (2008).
48 De Nardo, D. Toll-like receptors: Activation, signalling and transcriptional modulation. Cytokine
74, 181-189, doi:10.1016/j.cyto.2015.02.025 (2015).
49 Geijtenbeek, T. B., et al. C-type lectin receptors in the control of T helper cell differentiation. Nat
Rev Immunol 16, 433-448, doi:10.1038/nri.2016.55 (2016).
50 Chen, G., et al. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev
Pathol 4, 365-398, doi:10.1146/annurev.pathol.4.110807.092239 (2009).
51 Yoneyama, M., et al. Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol 32, 48-
53, doi:10.1016/j.coi.2014.12.012 (2015).
52 Iwasaki, A., et al. Control of adaptive immunity by the innate immune system. Nat Immunol 16,
343-353, doi:10.1038/ni.3123 (2015).
53 Kali?ski, P., et al.  T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a
third signal. Immunol today 20, 561-567 (1999).
54 Iwasaki, A., et al. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5,
987-995, doi:10.1038/ni1112 (2004).
55 Langenkamp, A., et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and
nonpolarized T cells. Nat Immunol 1, 311-316, doi:10.1038/79758 (2000).
56 Becattini, S., et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell
clones primed by pathogens or vaccines. Science 347, 400-406, doi:10.1126/science.1260668
(2015).
57 Jain, A., et al. Innate control of adaptive immunity: beyond the three-signal paradigm. J
Immunol 198, 3791-3800, doi:10.4049/jimmunol.1602000 (2017).
58 Schreiber, R. D., et al. Cancer immunoediting: integrating immunity’s roles in cancer
suppression and promotion. Science 331, 1565-1570 (2011).
59 Dunn, G. P., et al. The three Es of cancer immunoediting. Annu Rev Immunol 22, 329-360,
doi:10.1146/annurev.immunol.22.012703.104803 (2004).
60 Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer
12, 252-264, doi:10.1038/nrc3239 (2012).
61 Liu, L., et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade
effectively inhibits growth of triple negative breast cancer. Mol Ther 26, 45-55,
doi:10.1016/j.ymthe.2017.10.020 (2018).
References
65
62 Kang, T., et al. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with
tailored immune-stimulatory modality. Biomaterials 164, 80-97,
doi:10.1016/j.biomaterials.2018.02.033 (2018).
63 Ylosmaki, E., et  al. Personalized cancer vaccine platform for clinically relevant oncolytic
enveloped viruses. Mol Ther 26, 2315-2325, doi:10.1016/j.ymthe.2018.06.008 (2018).
64 Feola, S., et al. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and
poorly immunogenic tumors. Oncoimmunology 7, e1457596,
doi:10.1080/2162402X.2018.1457596 (2018).
65 Deng, H., et al. The application of nanotechnology in immune checkpoint blockade for cancer
treatment. J Control Release 290, 28-45, doi:10.1016/j.jconrel.2018.09.026 (2018).
66 Zylberberg, C., et al. Pharmaceutical liposomal drug delivery: a review of new delivery systems
and a look at the regulatory landscape. Drug Deliv 23, 3319-3329,
doi:10.1080/10717544.2016.1177136 (2016).
67 Petros, R. A., et al. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev
Drug Discov 9, 615-627, doi:10.1038/nrd2591 (2010).
68 Shi, J., et al. Nanotechnology in drug delivery and tissue engineering: from discovery to
applications. Nano Lett 10, 3223-3230, doi:10.1021/nl102184c (2010).
69 Kamaly, N., et al. Degradable controlled-release polymers and polymeric nanoparticles:
mechanisms of controlling drug release. Chem Rev 116, 2602-2663,
doi:10.1021/acs.chemrev.5b00346 (2016).
70 Bobo, D., et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical
trials to date. Pharm Res 33, 2373-2387, doi:10.1007/s11095-016-1958-5 (2016).
71 Griffin, B. T., et  al. Pharmacokinetic, pharmacodynamic and biodistribution following oral
administration of nanocarriers containing peptide and protein drugs. Adv Drug Deliv Rev 106,
367-380, doi:10.1016/j.addr.2016.06.006 (2016).
72 Petschauer, J. S., et al. The  effects  of  nanoparticle  drug  loading  on  the  pharmacokinetics  of
anticancer agents. Nanomedicine 10, 447-463 (2015).
73 Kai, M. P., et al. Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-
containing hydrogel nanoparticle. J Control Release 204, 70-77,
doi:10.1016/j.jconrel.2015.03.001 (2015).
74 Barenholz, Y. C. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release
160, 117-134 (2012).
75 Wang, A. Z., et al. Nanoparticle delivery of cancer drugs. Annu Rev Med 63, 185-198,
doi:10.1146/annurev-med-040210-162544 (2012).
76 Spencer, D. S., et al. Intelligent nanoparticles for advanced drug delivery in cancer treatment.
Curr Opin Chem Eng 7, 84-92, doi:10.1016/j.coche.2014.12.003 (2015).
77 Ball, R. L., et al. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA.
Nano Lett 18, 3814-3822, doi:10.1021/acs.nanolett.8b01101 (2018).
78 Kemp, J. A., et al. "Combo" nanomedicine: co-delivery of multi-modal therapeutics for efficient,
targeted, and safe cancer therapy. Adv Drug Deliv Rev 98, 3-18, doi:10.1016/j.addr.2015.10.019
(2016).
79 Mu, J., et al. Development of endogenous enzyme-responsive nanomaterials for theranostics.
Chem Soc Rev 47, 5554-5573, doi:10.1039/c7cs00663b (2018).
80 Muthu, M. S., et al. Nanotheranostics? application and further development of nanomedicine
strategies for advanced theranostics. Theranostics 4, 660 (2014).
81 Wilhelm, S., et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1, 16014 (2016).
82 Ke, P. C., et al..  A  decade  of  the  protein  corona. ACS Nano 11, 11773-11776,
doi:10.1021/acsnano.7b08008 (2017).
83 Wan, S., et al. The "sweet" side of the protein corona: effects of glycosylation on nanoparticle-cell
interactions. ACS Nano 9, 2157-2166, doi:10.1021/nn506060q (2015).
84 Ritz, S., et  al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake.
Biomacromolecules 16, 1311-1321 (2015).
85 Bertoli, F., et al. The intracellular destiny of the protein corona: a Study on its cellular
internalization and evolution. ACS Nano 10, 10471-10479, doi:10.1021/acsnano.6b06411 (2016).
86 Saha, K., et  al. Regulation of macrophage recognition through the interplay of nanoparticle
surface functionality and protein corona. ACS nano 10, 4421-4430 (2016).
87 Cheng, C. J., et al. A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev
Drug Discov 14, 239-247, doi:10.1038/nrd4503 (2015).
88 Klippstein, R., et al. Nanotechnology-based manipulation of dendritic cells for enhanced
immunotherapy strategies. Nanomedicine 6, 523-529, doi:10.1016/j.nano.2010.01.001 (2010).
89 Tran, T. H., et al. Nanoparticles for dendritic cell-based immunotherapy. Int J Pharm 542, 253-
265, doi:10.1016/j.ijpharm.2018.03.029 (2018).
90 Fontana, F., et al. in Theranostic Biomaterials (ed Elsevier B.V.)  (2019).
References
66
91 Fifis, T., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-
vaccines against tumors. J Immunol 173, 3148-3154 (2004).
92 Zubris, K. A., et  al. Ease  of  synthesis,  controllable  sizes,  and  in  vivo  large-animal-lymph
migration of polymeric nanoparticles. ChemMedChem 5, 1435-1438,
doi:10.1002/cmdc.201000250 (2010).
93 Hickey, J. W., et al. Control of polymeric nanoparticle size to improve therapeutic delivery. J
Control Release 219, 536-547, doi:10.1016/j.jconrel.2015.10.006 (2015).
94 Sharma, G., et al. Polymer particle shape independently influences binding and internalization
by macrophages. J Control Release 147, 408-412, doi:10.1016/j.jconrel.2010.07.116 (2010).
95 Kumar, S., et al. Shape and size-dependent immune response to antigen-carrying nanoparticles.
J Control Release 220, 141-148, doi:10.1016/j.jconrel.2015.09.069 (2015).
96 Truong, N. P., et al. The importance of nanoparticle shape in cancer drug delivery. Expert Opin
Drug Deliv 12, 129-142, doi:10.1517/17425247.2014.950564 (2015).
97 Gause, K. T., et al. Immunological principles guiding the rational design of particles for vaccine
delivery. ACS Nano 11, 54-68, doi:10.1021/acsnano.6b07343 (2017).
98 Dobrovolskaia, M. A., et al. Immunological properties of engineered nanomaterials. Nat
Nanotechnol 2, 469-478, doi:10.1038/nnano.2007.223 (2007).
99 Albanese, A., et al. The  effect  of  nanoparticle  size,  shape,  and  surface  chemistry  on  biological
systems. Annu Rev Biomed Eng 14, 1-16, doi:10.1146/annurev-bioeng-071811-150124 (2012).
100 Shima, F., et al. Manipulating the antigen-specific immune response by the hydrophobicity of
amphiphilic poly(gamma-glutamic acid) nanoparticles. Biomaterials 34, 9709-9716,
doi:10.1016/j.biomaterials.2013.08.064 (2013).
101 Nel, A. E., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat
Mater 8, 543-557, doi:10.1038/nmat2442 (2009).
102 Seong, S. Y., et al.  Hydrophobicity: an ancient damage-associated molecular pattern that
initiates innate immune responses. Nat Rev Immunol 4, 469-478, doi:10.1038/nri1372 (2004).
103 Merkel, T. J., et  al. Using  mechanobiological  mimicry  of  red  blood  cells  to  extend  circulation
times of hydrogel microparticles. Proc Natl Acad Sci U S A (2010).
104 Cui, J., et al. Mechanically tunable, self-adjuvanting nanoengineered polypeptide particles. Adv
Mater 25, 3468-3472, doi:10.1002/adma.201300981 (2013).
105 Benne, N., et al. Orchestrating  immune  responses:  How  size,  shape  and  rigidity  affect  the
immunogenicity of particulate vaccines. J Control Release 234, 124-134 (2016).
106 Liu, L., et al. Immune responses to vaccines delivered by encapsulation into and/or adsorption
onto cationic lipid-PLGA hybrid nanoparticles. J Control Release 225, 230-239 (2016).
107 Reddy, S. T., et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide)
nanoparticles. J Control Release 112, 26-34, doi:10.1016/j.jconrel.2006.01.006 (2006).
108 Li, X., et al. Relationship between the size of nanoparticles and their adjuvant activity: data from
a study with an improved experimental design. Eur J Pharm Biopharm 78, 107-116 (2011).
109 Hirai, T., et al. Amorphous silica nanoparticles enhance cross-presentation in murine dendritic
cells. Biochem Biophys Res Commun 427, 553-556, doi:10.1016/j.bbrc.2012.09.095 (2012).
110 Shao, D., et  al. The  shape  effect  of  magnetic  mesoporous  silica  nanoparticles  on  endocytosis,
biocompatibility and biodistribution. Acta Biomater 49, 531-540,
doi:10.1016/j.actbio.2016.11.007 (2017).
111 Huang, X., et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance,
and biocompatibility in vivo. ACS Nano 5, 5390-5399, doi:10.1021/nn200365a (2011).
112 Mathaes, R., et al. Influence of particle size, an elongated particle geometry, and adjuvants on
dendritic cell activation. Eur J Pharm Biopharm 94, 542-549, doi:10.1016/j.ejpb.2015.06.015
(2015).
113 Almalik, A., et al. Hyaluronic acid coated chitosan nanoparticles reduced the immunogenicity of
the formed protein corona. Sci Rep 7, 10542, doi:10.1038/s41598-017-10836-7 (2017).
114 Elci, S. G., et al. Surface charge controls the suborgan biodistributions of gold nanoparticles. ACS
Nano 10, 5536-5542, doi:10.1021/acsnano.6b02086 (2016).
115 Moyano, D. F., et  al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc
134, 3965-3967, doi:10.1021/ja2108905 (2012).
116 Anselmo, A. C., et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis,
endocytosis, and targeting. ACS nano 9, 3169-3177 (2015).
117 Christensen, D., et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium
lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing
capacity compared to its unsaturated analog. J Control Release 160, 468-476,
doi:10.1016/j.jconrel.2012.03.016 (2012).
118 Lybaert, L.,et al. Immunoengineering through cancer vaccines–A personalized and multi-step
vaccine approach towards precise cancer immunity. J Control Release (2018).
119 Wang, C., et al. Tailoring biomaterials for cancer immunotherapy: emerging trends and future
outlook. Adv Mater 29, doi:10.1002/adma.201606036 (2017).
References
67
120 Goldberg, M. S. Immunoengineering: how nanotechnology can enhance cancer immunotherapy.
Cell 161, 201-204 (2015).
121 Cheung, A. S. et al. Engineered materials for cancer immunotherapy. Nano Today 10, 511-531,
doi:10.1016/j.nantod.2015.06.007 (2015).
122 Ali, O. A., et al. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 8,
151-158, doi:10.1038/nmat2357 (2009).
123 Weiden, J., et al. Synthetic immune niches for cancer immunotherapy. Nat Rev Immunol 18,
212-219, doi:10.1038/nri.2017.89 (2018).
124 Ali, O. A., et al. In situ regulation of DC subsets and T cells mediates tumor regression in mice.
Sci Transl Med 1, 8ra19, doi:10.1126/scitranslmed.3000359 (2009).
125 Kim, J., et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells
in vivo and increase vaccine efficacy. Nat Biotechnol 33, 64-72, doi:10.1038/nbt.3071 (2015).
126 Bencherif, S. A., et al. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun 6, 7556,
doi:10.1038/ncomms8556 (2015).
127 Singh, A., et al. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and
siRNA–DNA carrying microparticles to dendritic cells. Biomaterials 30, 5187-5200 (2009).
128 Singh, A., et  al. An injectable synthetic immune-priming center mediates efficient T-cell class
switching  and  T-helper  1  response  against  B  cell  lymphoma. J Control Release 155, 184-192,
doi:10.1016/j.jconrel.2011.06.008 (2011).
129 Fesnak, A. D., et al. Engineered T cells: the promise and challenges of cancer immunotherapy.
Nat Rev Cancer 16, 566-581, doi:10.1038/nrc.2016.97 (2016).
130 Perica, K., et al. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells
for Adoptive Immunotherapy. ACS Nano 9, 6861-6871, doi:10.1021/acsnano.5b02829 (2015).
131 Oelke, M., et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-
coated artificial antigen-presenting cells. Nat Med 9, 619-624, doi:10.1038/nm869 (2003).
132 Meyer, R. A., et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen
specific T?cell activation. Small 11, 1519-1525 (2015).
133 Kanapathipillai, M., et al. Nanoparticle targeting of anti-cancer drugs that alter intracellular
signaling or influence the tumor microenvironment. Adv Drug Delivery Rev 79, 107-118 (2014).
134 Bauleth?Ramos, T., et  al. Nutlin-3a and cytokine co-loaded spermine-modified acetalated
dextran nanoparticles for cancer chemo-immunotherapy. Adv Funct Mater 27, 1703303 (2017).
135 Singh, Y., et  al. Targeting tumor associated macrophages (TAMs) via nanocarriers. J Control
Release 254, 92-106, doi:10.1016/j.jconrel.2017.03.395 (2017).
136 Rodell, C. B., et  al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-
associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng, 1 (2018).
137 Huang, Z., et  al. Targeted delivery of oligonucleotides into tumor-associated macrophages for
cancer immunotherapy. J Control Release 158, 286-292 (2012).
138 Wang, Y., et  al. Polymeric  nanoparticles  promote  macrophage  reversal  from  M2  to  M1
phenotypes in the tumor microenvironment. Biomaterials 112, 153-163,
doi:10.1016/j.biomaterials.2016.09.034 (2017).
139 Zeisberger, S. M., et  al. Clodronate-liposome-mediated depletion of tumour-associated
macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95, 272-
281, doi:10.1038/sj.bjc.6603240 (2006).
140 Conde, J. et  al., Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide
nanoparticles to tumor-associated macrophages and cancer cells. Adv Funct Mater 25, 4183-
4194 (2015).
141 Roy, A., et al. Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in
tumor regression and enhanced immune response in the tumor microenvironment of a mouse
model. Int J Pharm 445, 171-180, doi:10.1016/j.ijpharm.2013.01.045 (2013).
142 Makkouk, A., et al. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in
situ immunization against cancer. AAPS J 17, 184-193, doi:10.1208/s12248-014-9676-6 (2015).
143 Fontana, F., et al. Immunostimulation and immunosuppression: nanotechnology on the brink.
Small Methods 2, 1700347 (2018).
144 Hamdy, S., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA
nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26, 5046-
5057, doi:10.1016/j.vaccine.2008.07.035 (2008).
145 Han, H. D., et al. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide)
nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine 11, 5729-5742,
doi:10.2147/IJN.S109001 (2016).
146 Ahmed, K. K., et al. Development and evaluation of biodegradable particles coloaded with
antigen and the Toll-like receptor agonist, pentaerythritol lipid A, as a cancer vaccine. J Pharm
Sci 105, 1173-1179, doi:10.1016/j.xphs.2015.11.042 (2016).
147 Heit, A., et al. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity.
Eur J Immunol 37, 2063-2074, doi:10.1002/eji.200737169 (2007).
References
68
148 Dolen, Y., et  al. Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic
protein induce strong T cell-mediated antitumor immune responses. Oncoimmunology 5,
e1068493, doi:10.1080/2162402X.2015.1068493 (2016).
149 Shen, L., et al. A trifunctional dextran-based nanovaccine targets and activates murine dendritic
cells, and induces potent cellular and humoral immune responses in vivo. PLoS One 8, e80904,
doi:10.1371/journal.pone.0080904 (2013).
150 Zeng, Q., et al. Tailoring polymeric hybrid micelles with lymph node targeting ability to improve
the potency of cancer vaccines. Biomaterials 122, 105-113,
doi:10.1016/j.biomaterials.2017.01.010 (2017).
151 Persano, S., et  al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination.
Biomaterials 125, 81-89, doi:10.1016/j.biomaterials.2017.02.019 (2017).
152 Xu, Z., et al. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce
potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control
Release 172, 259-265, doi:10.1016/j.jconrel.2013.08.021 (2013).
153 Hassan, H. A., et al. Dual stimulation of antigen presenting cells using carbon nanotube-based
vaccine delivery system for cancer immunotherapy. Biomaterials 104, 310-322 (2016).
154 Neumann, S., et  al. Synthetic TRP2 long-peptide and ?-galactosylceramide formulated into
cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression. Vaccine 33,
5838-5844 (2015).
155 Molino, N. M., et al. Biomimetic protein nanoparticles facilitate enhanced dendritic cell
activation and cross-presentation. ACS Nano 7, 9743-9752, doi:10.1021/nn403085w (2013).
156 Zhang, P., et al. Polyelectrolyte  multilayers  assembled  entirely  from  immune  signals  on  gold
nanoparticle templates promote antigen-specific T cell response. ACS Nano 9, 6465-6477,
doi:10.1021/acsnano.5b02153 (2015).
157 Neek, M., et  al. Co-delivery of human cancer-testis antigens with adjuvant in protein
nanoparticles induces higher cell-mediated immune responses. Biomaterials 156, 194-203,
doi:10.1016/j.biomaterials.2017.11.022 (2018).
158 Zhang, C., et al. Targeted antigen delivery to dendritic cell via functionalized alginate
nanoparticles for cancer immunotherapy. J Control Release 256, 170-181,
doi:10.1016/j.jconrel.2017.04.020 (2017).
159 Liu, Q., et  al. pH-responsive poly(D,L-lactic-co-glycolic acid) nanoparticles with rapid antigen
release behavior promote immune response. ACS Nano 9, 4925-4938, doi:10.1021/nn5066793
(2015).
160 Shi, G. N., et al. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-
loaded chitosan nanoparticles vaccine. Biomaterials 113, 191-202,
doi:10.1016/j.biomaterials.2016.10.047 (2017).
161 Yang, Y., et  al. Multi-shelled dendritic mesoporous organosilica hollow spheres: roles of
composition and architecture in cancer immunotherapy. Angew Chem Int Ed Engl 56, 8446-
8450, doi:10.1002/anie.201701550 (2017).
162 Wang, C., et al. Inflammation-triggered cancer immunotherapy by programmed delivery of CpG
and Anti-PD1 antibody. Adv Mater 28, 8912-8920, doi:10.1002/adma.201506312 (2016).
163 Luo, M., et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol 12,
648-654, doi:10.1038/nnano.2017.52 (2017).
164 Yoshizaki, Y., et al. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid
inclusion as antigen delivery carriers for cancer immunotherapy. Biomaterials 35, 8186-8196,
doi:10.1016/j.biomaterials.2014.05.077 (2014).
165 Yuba, E., et  al. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy.
Biomaterials 35, 3091-3101, doi:10.1016/j.biomaterials.2013.12.024 (2014).
166 Lebel, M.-È., et  al. Potentiating cancer immunotherapy using papaya mosaic virus-derived
nanoparticles. Nano Lett 16, 1826-1832 (2016).
167 Ochyl, L. J., et al. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer
immunotherapy. Biomaterials 182, 157-166 (2018).
168 Kuai, R., et  al. Subcutaneous nanodisc vaccination with neoantigens for combination cancer
immunotherapy. Bioconjug Chem 29, 771-775, doi:10.1021/acs.bioconjchem.7b00761 (2018).
169 Rodriguez, P. L ., et  al. Minimal" Self" peptides that inhibit  phagocytic clearance and enhance
delivery of nanoparticles. Science 339, 971-975 (2013).
170 Qie, Y., et al. Surface  modification  of  nanoparticles  enables  selective  evasion  of  phagocytic
clearance by distinct macrophage phenotypes. Sci Rep 6, 26269, doi:10.1038/srep26269 (2016).
171 Villa, C. H., et al. Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and
inspiration for advanced delivery systems. Adv Drug Delivery Rev 106, 88-103 (2016).
172 Brenner, J. S., et al. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs
by orders of magnitude. Nat Commun 9, 2684, doi:10.1038/s41467-018-05079-7 (2018).
173 Pan, D. C., et  al. Nanoparticle properties modulate their attachment and effect on carrier red
blood cells. Sci Rep 8, 1615 (2018).
References
69
174 Wibroe, P. P., et  al. Bypassing adverse injection reactions to nanoparticles through shape
modification and attachment to erythrocytes. Nat Nanotechnol 12, 589 (2017).
175 Chambers, E. et al. Long circulating nanoparticles via adhesion on red blood cells: mechanism
and extended circulation. Exp Biol Med (Maywood) 232, 958-966 (2007).
176 Balasubramanian, V., et al. Biomimetic engineering using cancer cell membranes for designing
compartmentalized nanoreactors with organelle?like functions. Adv Mater 29, 1605375 (2017).
177 Diez-Silva, M., et al. Shape and biomechanical characteristics of human red blood cells in health
and disease. MRS Bull 35, 382-388 (2010).
178 Huang, Y. X., et al. Restoring the youth of aged red blood cells and extending their lifespan in
circulation by remodelling membrane sialic acid. J Cell Mol Med 20, 294-301 (2016).
179 Pivkin, I. V., et al. Biomechanics  of  red  blood  cells  in  human  spleen  and  consequences  for
physiology and disease. Proc Natl Acad Sci U S A 113, 7804-7809, doi:10.1073/pnas.1606751113
(2016).
180 de Back, D. Z., et al. Of macrophages and red blood cells; a complex love story. Front Physiol 5,
9, doi:10.3389/fphys.2014.00009 (2014).
181 Gao, M., et  al. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red
blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater 29, 1701429
(2017).
182 Ren, X., et al. Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided
photothermal therapy. Biomaterials 92, 13-24, doi:10.1016/j.biomaterials.2016.03.026 (2016).
183 Luk, B. T., et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug
delivery to treat solid tumors. Theranostics 6, 1004-1011, doi:10.7150/thno.14471 (2016).
184 Piao, J.-G., et al. Erythrocyte  membrane  is  an  alternative  coating  to  polyethylene  glycol  for
prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 8,
10414-10425 (2014).
185 Su, J. et al., Enhanced blood suspensibility and laser-activated tumor-specific drug release of
theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes.
Theranostics 7, 523-537, doi:10.7150/thno.17259 (2017).
186 Peng, J., et al. Erythrocyte-membrane-coated prussian blue/manganese dioxide nanoparticles as
H2O2-responsive oxygen generators to enhance cancer chemotherapy/photothermal therapy.
ACS Appl Mater Interfaces 9, 44410-44422, doi:10.1021/acsami.7b17022 (2017).
187 Wang, F., et  al. Nanoparticle-based antivirulence vaccine for the management of methicillin-
resistant staphylococcus aureus skin infection. Adv Funct Mater 26, 1628-1635,
doi:10.1002/adfm.201505231 (2016).
188 Wei, X., et  al. In situ capture of bacterial toxins for antivirulence vaccination. Adv Mater 29,
doi:10.1002/adma.201701644 (2017).
189 Guo, Y., et  al. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for
induction of antitumor immunity against melanoma. ACS nano 9, 6918-6933 (2015).
190 Fang, R. H., et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-
cloaked nanoparticles. Nanoscale 5, 8884-8888, doi:10.1039/c3nr03064d (2013).
191 Hu, C.-M. J., et al.  A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol
8, 336 (2013).
192 Pang, Z., et al. Detoxification of organophosphate poisoning using nanoparticle bioscavengers.
ACS nano 9, 6450-6458 (2015).
193 Nguyen, T. D. T., et al. Engineered biomimetic nanoabsorbent for cellular detoxification of
chemotherapeutics. RSC Advances 6, 33003-33008 (2016).
194 Copp, J. A., et al. Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl
Acad Sci U S A 111, 13481-13486 (2014).
195 Chen, H. W., et al. Targeting and enrichment of viral pathogen by cell membrane cloaked
magnetic nanoparticles for enhanced detection. ACS Appl Mater Interfaces 9, 39953-39961,
doi:10.1021/acsami.7b09931 (2017).
196 Jenne, C. N., et al. Platelets in inflammation and infection. Platelets 26, 286-292,
doi:10.3109/09537104.2015.1010441 (2015).
197 Walsh, T. G., et al. The functional role of platelets in the regulation of angiogenesis. Platelets 26,
199-211, doi:10.3109/09537104.2014.909022 (2015).
198 Fontana, F., et  al. Platelet lysate-modified porous silicon microparticles for enhanced cell
proliferation in wound healing applications. ACS Appl Mater Interfaces 8, 988-996,
doi:10.1021/acsami.5b10950 (2016).
199 Hu, C. M., et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118-
121, doi:10.1038/nature15373 (2015).
200 Frangogiannis, N. G. The inflammatory response in myocardial injury, repair, and remodelling.
Nat Rev Cardiol 11, 255-265, doi:10.1038/nrcardio.2014.28 (2014).
201 Kreuger, J., et al. Targeting vascular and leukocyte communication in angiogenesis,
inflammation and fibrosis. Nat Rev Drug Discov 15, 125-142, doi:10.1038/nrd.2015.2 (2016).
References
70
202 Navegantes, K. C., et al. Immune modulation of some autoimmune diseases: the critical role of
macrophages and neutrophils in the innate and adaptive immunity. J Transl Med 15, 36 (2017).
203 Parodi, A., et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes
possess cell-like functions. Nat Nanotechnol 8, 61-68, doi:10.1038/nnano.2012.212 (2013).
204 Xuan, M., et al. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in
vivo cancer therapy. Adv Healthc Mater 4, 1645-1652, doi:10.1002/adhm.201500129 (2015).
205 Cao, H., et al. Liposomes coated with isolated macrophage membrane can target lung metastasis
of breast cancer. ACS nano 10, 7738-7748 (2016).
206 Xuan, M., et al. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged
circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces 8, 9610-
9618, doi:10.1021/acsami.6b00853 (2016).
207 Thamphiwatana, S., et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and
proinflammatory cytokines for sepsis management. Proc Natl Acad Sci U S A 114, 11488-11493,
doi:10.1073/pnas.1714267114 (2017).
208 Xiong, K. et al., Biomimetic immuno-magnetosomes for high-performance enrichment of
circulating tumor cells. Adv Mater 28, 7929-7935, doi:10.1002/adma.201601643 (2016).
209 Gao, C., et al. Polymeric capsule-cushioned leukocyte cell  membrane vesicles as a biomimetic
delivery platform. Nanoscale 8, 3548-3554, doi:10.1039/c5nr08407e (2016).
210 Kidd, S., et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding
microenvironments using in vivo bioluminescent imaging. Stem Cells 27, 2614-2623,
doi:10.1002/stem.187 (2009).
211 Layek, B., et al. Nano-engineered mesenchymal stem cells increase therapeutic efficacy of
anticancer drug through true active tumor targeting. Mol Cancer Ther 17, 1196-1206,
doi:10.1158/1535-7163.MCT-17-0682 (2018).
212 Tang, J., et  al. Therapeutic microparticles functionalized with biomimetic cardiac stem cell
membranes and secretome. Nat Commun 8, 13724, doi:10.1038/ncomms13724 (2017).
213 Gao, W., et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles.
Nano Lett 15, 1403-1409, doi:10.1021/nl504798g (2015).
214 Rao, L., et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation
time and reduced accelerated blood clearance. Small 11, 6225-6236 (2015).
215 Rao, L., et al. Erythrocyte membrane-coated upconversion nanoparticles with minimal protein
adsorption for enhanced tumor imaging. ACS  Appl  Mater  Interfaces 9, 2159-2168,
doi:10.1021/acsami.6b14450 (2017).
216 Jiang, Q., et  al. Red blood cell membrane-camouflaged melanin nanoparticles for enhanced
photothermal therapy. Biomaterials 143, 29-45, doi:10.1016/j.biomaterials.2017.07.027 (2017).
217 Ding, H., et  al. Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with
programmed delivery for photodynamic therapy of cancer. Nanoscale 7, 9806-9815 (2015).
218 Deng, J., et al. Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced X-
ray radiation therapy of breast cancer. Biomaterials 154, 24-33,
doi:10.1016/j.biomaterials.2017.10.048 (2018).
219 Ren, H., et  al. Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes
for long circulation and enhanced phototherapy. Acta Biomater 59, 269-282,
doi:10.1016/j.actbio.2017.06.035 (2017).
220 Chai, Z., et  al. A  facile  approach  to  functionalizing  cell  membrane-coated  nanoparticles  with
neurotoxin-derived peptide for brain-targeted drug delivery. J Control Release 264, 102-111,
doi:10.1016/j.jconrel.2017.08.027 (2017).
221 Su, J., et al. Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor
penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv Funct
Mater 26, 1243-1252 (2016).
222 Chhabria, V., et al. Development of nanosponges from erythrocyte ghosts for removal of
streptolysin-O from mammalian blood. Nanomedicine (Lond), doi:10.2217/nnm-2016-0180
(2016).
223 Escajadillo, T., et al. A red blood cell membrane-camouflaged nanoparticle counteracts
streptolysin O-mediated virulence phenotypes of invasive group A streptococcus. Front
Pharmacol 8, 477, doi:10.3389/fphar.2017.00477 (2017).
224 Chen, M. S., et al. Fabrication and characterization of a 3D bioprinted nanoparticle-hydrogel
hybrid device for biomimetic detoxification. Nanoscale 9, 14506-14511, doi:10.1039/c7nr05322c
(2017).
225 Wu, Z., et  al. Cell-membrane-coated synthetic nanomotors for effective biodetoxification. Adv
Funct Mater 25, 3881-3887 (2015).
226 Hu, C. M., et al. Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol
8, 933-938, doi:10.1038/nnano.2013.254 (2013).
227 Lapek, J. D., Jr., et al. Biomimetic virulomics for capture and identification of cell-type specific
effector proteins. ACS Nano 11, 11831-11838, doi:10.1021/acsnano.7b02650 (2017).
References
71
228 Fu, Q., et  al. Programmed  co-delivery  of  paclitaxel  and  doxorubicin  boosted  by  camouflaging
with erythrocyte membrane. Nanoscale 7, 4020-4030, doi:10.1039/c4nr07027e (2015).
229 Su, J., et  al. Bioinspired nanoparticles with NIR-controlled drug release for synergetic
chemophotothermal therapy of metastatic breast cancer. Adv Funct Mater 26, 7495-7506 (2016).
230 Rao, L., et al. Photocatalytic degradation of cell membrane coatings for controlled drug release.
Adv Healthc Mater 5, 1420-1427, doi:10.1002/adhm.201600303 (2016).
231 Gao, L., et  al. Erythrocyte membrane-wrapped pH sensitive polymeric nanoparticles for non-
small cell lung cancer therapy. Bioconjug Chem 28, 2591-2598,
doi:10.1021/acs.bioconjchem.7b00428 (2017).
232 Song, Q., et  al. Tumor microenvironment responsive nanogel for the combinatorial antitumor
effect of chemotherapy and immunotherapy. Nano Lett 17, 6366-6375,
doi:10.1021/acs.nanolett.7b03186 (2017).
233 Li, L. L., et  al. Core-shell supramolecular gelatin nanoparticles for adaptive and "on-demand"
antibiotic delivery. ACS Nano 8, 4975-4983, doi:10.1021/nn501040h (2014).
234 Zhang, Y., et al. Erythrocyte membrane-coated nanogel for combinatorial antivirulence and
responsive antimicrobial delivery against Staphylococcus aureus infection. J Control Release
263, 185-191, doi:10.1016/j.jconrel.2017.01.016 (2017).
235 Gao, L., et al. An effective intracellular delivery system of monoclonal antibody for treatment of
tumors: erythrocyte membrane-coated self-associated antibody nanoparticles. Nanotechnology
28, 335101, doi:10.1088/1361-6528/aa7c43 (2017).
236 Fu, Y., et  al. Erythrocyte-membrane-camouflaged nanoplatform for intravenous glucose-
responsive insulin delivery. Adv Funct Mater 28, 1802250 (2018).
237 Zhang, X., et al. Remote loading of small-molecule therapeutics into cholesterol-enriched cell-
membrane-derived vesicles. Angew  Chem  Int  Ed  Engl 56, 14075-14079,
doi:10.1002/anie.201707598 (2017).
238 Hu, Q., et  al. Anticancer platelet-mimicking nanovehicles. Adv Mater 27, 7043-7050,
doi:10.1002/adma.201503323 (2015).
239 Wei, X., et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for
the treatment of immune thrombocytopenia. Biomaterials 111, 116-123 (2016).
240 Li, J., et  al. Targeted  drug  delivery  to  circulating  tumor  cells  via  platelet  membrane-
functionalized particles. Biomaterials 76, 52-65, doi:10.1016/j.biomaterials.2015.10.046 (2016).
241 Hu, Q., et  al. Engineered nanoplatelets for enhanced treatment of multiple myeloma and
thrombus. Adv Mater 28, 9573-9580, doi:10.1002/adma.201603463 (2016).
242 Krishnamurthy, S., et  al. Monocyte cell membrane-derived nanoghosts for targeted cancer
therapy. Nanoscale 8, 6981-6985, doi:10.1039/c5nr07588b (2016).
243 Kang, T., et  al. Nanoparticles coated with neutrophil membranes can effectively treat cancer
metastasis. ACS Nano 11, 1397-1411 (2017).
244 Rao, L., et  al. Effective cancer targeting and imaging using macrophage membrane ?
camouflaged upconversion nanoparticles. J. Biomed. Mater. Res., Part A 105, 521-530 (2017).
245 Zhang, Q., et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and
alleviate joint damage in inflammatory arthritis. Nat Nanotechnol, doi:10.1038/s41565-018-
0254-4 (2018).
246 Wang, C., et  al. Pretreated macrophage-membrane-coated gold nanocages for precise drug
delivery for treatment of bacterial infections. Adv Mater, e1804023,
doi:10.1002/adma.201804023 (2018).
247 Zhang, L., et  al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles
combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer.
Int J Nanomedicine 12, 2129-2142, doi:10.2147/IJN.S126016 (2017).
248 Gao, C., et  al. Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted
drug delivery. Small 12, 4056-4062, doi:10.1002/smll.201600624 (2016).
249 Bose, R. J., et al. Bioengineered stem cell membrane functionalized nanocarriers for therapeutic
targeting of severe hindlimb ischemia. Biomaterials 185, 360-370,
doi:10.1016/j.biomaterials.2018.08.018 (2018).
250 Lai, P.-Y., et al. Biomimetic stem cell membrane-camouflaged iron oxide nanoparticles for
theranostic applications. RSC Adv 5, 98222-98230 (2015).
251 Gao, C., et al. Stem-cell-membrane camouflaging on near-infrared photoactivated upconversion
nanoarchitectures for in vivo remote-controlled photodynamic therapy. ACS Appl Mater
Interfaces 8, 34252-34260, doi:10.1021/acsami.6b12865 (2016).
252 Silva, A. K. A., et al. Cell-derived vesicles as a bioplatform for the encapsulation of theranostic
nanomaterials. Nanoscale 5, 11374-11384 (2013).
253 Chen, W., et al. Coating nanofiber scaffolds with beta cell membrane to promote cell proliferation
and function. Nanoscale 8, 10364-10370, doi:10.1039/c6nr00535g (2016).
254 Dehaini, D., et al. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle
functionalization. Adv Mater 29, 1606209 (2017).
References
72
255 Rao, L., et  al. Platelet-leukocyte hybrid membrane-coated immunomagnetic beads for highly
efficient and highly specific isolation of circulating tumor cells. Adv Funct Mater 28, 1803531
(2018).
256 He, H., et al. Leutusome: a biomimetic nanoplatform integrating plasma membrane components
of leukocytes and tumor cells for remarkably enhanced solid tumor homing. Nano Lett 18, 6164-
6174, doi:10.1021/acs.nanolett.8b01892 (2018).
257 Liang, H., et al. Mesenchymal stem cell/red blood cell-inspired nanoparticle therapy in mice with
carbon tetrachloride-induced acute liver failure. ACS Nano 12, 6536-6544,
doi:10.1021/acsnano.8b00553 (2018).
258 Zhu, J. Y., et  al. Preferential cancer cell self-recognition and tumor self-targeting by coating
nanoparticles with homotypic cancer cell membranes. Nano Lett 16, 5895-5901,
doi:10.1021/acs.nanolett.6b02786 (2016).
259 Sun, H., et al. Cancer cell membrane-coated gold nanocages with hyperthermia-triggered drug
release and homotypic target inhibit growth and metastasis of breast cancer. Adv Funct Mater
27, 1604300 (2017).
260 Rao, L., et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor
imaging. Adv Mater 28, 3460-3466, doi:10.1002/adma.201506086 (2016).
261 Cheng, H., et al. An O2 self-sufficient biomimetic nanoplatform for highly specific and efficient
photodynamic therapy. Adv Funct Mater 26, 7847-7860 (2016).
262 Li, S. Y., et  al. Cancer cell membrane-coated biomimetic platform for tumor targeted
photodynamic therapy and hypoxia-amplified bioreductive therapy. Biomaterials 142, 149-161,
doi:10.1016/j.biomaterials.2017.07.026 (2017).
263 Sun, H., et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors.
Adv Mater 28, 9581-9588, doi:10.1002/adma.201602173 (2016).
264 Tian, H., et  al. Cancer cell membrane-biomimetic oxygen nanocarrier for breaking hypoxia-
induced chemoresistance. Adv Funct Mater 27, 1703197 (2017).
265 Chen, Z., et al. Cancer cell membrane–biomimetic nanoparticles for homologous-targeting dual-
modal imaging and photothermal therapy. ACS nano 10, 10049-10057 (2016).
266 Li, S. Y., et al. A biomimetic theranostic O2-meter for cancer targeted photodynamic therapy and
phosphorescence imaging. Biomaterials 151, 1-12, doi:10.1016/j.biomaterials.2017.10.021
(2018).
267 Li, S. Y., et  al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted
starvation and photodynamic therapy. ACS Nano 11, 7006-7018, doi:10.1021/acsnano.7b02533
(2017).
268 Cheung, A. S., et al. Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for
cancer vaccination. Small 12, 2321-2333, doi:10.1002/smll.201600061 (2016).
269 Patel, J. M., et al. Plasma membrane vesicles decorated with glycolipid-anchored antigens and
adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth.
Biomaterials 74, 231-244, doi:10.1016/j.biomaterials.2015.09.031 (2016).
270 Tian, X., et  al. A membrane vesicle-based dual vaccine against melanoma and Lewis lung
carcinoma. Biomaterials 33, 6147-6154, doi:10.1016/j.biomaterials.2012.05.034 (2012).
271 Vinay, D. S., et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin
Cancer Biol 35 Suppl, S185-S198, doi:10.1016/j.semcancer.2015.03.004 (2015).
272 Mohme, M., et al. Circulating and disseminated tumour cells - mechanisms of immune
surveillance and escape. Nat Rev Clin Oncol 14, 155-167, doi:10.1038/nrclinonc.2016.144 (2017).
273 van der Burg, S. H., et al. Vaccines for established cancer: overcoming the challenges posed by
immune evasion. Nat Rev Cancer 16, 219-233, doi:10.1038/nrc.2016.16 (2016).
274 Ali, O. A., et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell
activity and tumor eradication. Cancer Immunol Res 4, 95-100, doi:10.1158/2326-6066.CIR-14-
0126 (2016).
275 Gotwals, P., et  al. Prospects for combining targeted and conventional cancer therapy with
immunotherapy. Nat Rev Cancer 17, 286-301, doi:10.1038/nrc.2017.17 (2017).
276 Chung, C. K., et al. Combinatory therapy adopting nanoparticle-based cancer vaccination with
immune checkpoint blockade for treatment of post-surgical tumor recurrences. J Control Release
285, 56-66, doi:10.1016/j.jconrel.2018.07.011 (2018).
277 Uhlir Jr, A. Electrolytic shaping of germanium and silicon. Bell Syst. Tech. J. 35, 333-347 (1956).
278 Canham, L. T. Bioactive silicon structure fabrication through nanoetching techniques. Adv Mater
7, 1033-1037 (1995).
279 Salonen, J., et al. Fabrication and chemical surface modification of mesoporous silicon for
biomedical applications. Chem. Eng. J. 137, 162-172 (2008).
280 Bley, R. A., et al. Characterization of silicon nanoparticles prepared from porous silicon. Chem.
Mater. 8, 1881-1888 (1996).
281 Heinrich, J. L., et al. Luminescent colloidal silicon suspensions from porous silicon. Science 255,
66-68 (1992).
References
73
282 Salonen, J., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release
of five model drugs. J Control Release 108, 362-374, doi:10.1016/j.jconrel.2005.08.017 (2005).
283 Roberts, D. S., et  al. Preparation of photoluminescent porous silicon nanoparticles by high-
pressure microfluidization. Part. Part. Syst. Charact. 34, 1600326 (2017).
284 Chiappini, C., et al. Tailored porous silicon microparticles: fabrication and properties. Chem Phys
Chem 11, 1029-1035, doi:10.1002/cphc.200900914 (2010).
285 Alhmoud, H.. et al. Porous silicon nanodiscs for targeted drug delivery. Adv Funct Mater 25,
1137-1145 (2015).
286 Elnathan, R.. et al. Maximizing transfection efficiency of vertically aligned silicon nanowire
arrays. Adv Funct Mater 25, 7215-7225 (2015).
287 Dai, F.. et  al. Bottom-up  synthesis  of  high  surface  area  mesoporous  crystalline  silicon  and
evaluation of its hydrogen evolution performance. Nat Commun 5, 3605,
doi:10.1038/ncomms4605 (2014).
288 Fan, D., et al. The role of nanostructured mesoporous silicon in discriminating in vitro
calcification for electrospun composite tissue engineering scaffolds. Nanoscale 3, 354-361 (2011).
289 Park, J.-H., et al. Biodegradable luminescent porous silicon nanoparticles for in vivo applications.
Nat Mater 8, 331 (2009).
290 Shabir, Q., et  al. Quantification and reduction of the residual chemical reactivity of passivated
biodegradable porous silicon for drug delivery applications. Silicon 10, 349-359 (2018).
291 Kovalev, D., et al. Photodegradation of porous silicon induced by photogenerated singlet oxygen
molecules. Appl Phys Lett 85, 3590-3592 (2004).
292 Low, S. P., et al. Generation of reactive oxygen species from porous silicon microparticles in cell
culture medium. J. Biomed. Mater. Res., Part A 93, 1124-1131 (2010).
293 Pap, A. E., et  al. Thermal  oxidation  of  porous  silicon:  study  on  structure. Appl  Phys  Lett 86,
041501 (2005).
294 Aggarwal, G., et al. Porous  silicon  surface  stability:  a  comparative  study  of  thermal  oxidation
techniques. J Porous Mater 21, 23-29 (2014).
295 Bimbo, L. M., et  al. Cellular interactions of surface modified nanoporous silicon particles.
Nanoscale 4, 3184-3192, doi:10.1039/c2nr30397c (2012).
296 Salonen, J., et al. Stabilization of porous silicon surface by thermal decomposition of acetylene.
Appl Surf Sci 225, 389-394 (2004).
297 Salonen, J., et al. Thermal carbonization of porous silicon surface by acetylene. J Appl Phys 91,
456-461 (2002).
298 Salonen, J., et al.  Studies of thermally?carbonized porous silicon surfaces. Phys Status Solidi A
182, 123-126 (2000).
299 Makila, E., et al. Amine modification of thermally carbonized porous silicon with silane coupling
chemistry. Langmuir 28, 14045-14054, doi:10.1021/la303091k (2012).
300 Anderson, S., et al. Dissolution  of  different  forms  of  partially  porous  silicon  wafers  under
simulated physiological conditions. Phys Status Solidi A 197, 331-335 (2003).
301 Santos, H. A., et  al. In vitro cytotoxicity of porous silicon microparticles: effect of the particle
concentration, surface chemistry and size. Acta Biomater 6, 2721-2731,
doi:10.1016/j.actbio.2009.12.043 (2010).
302 Martinez, J. O., et  al. Degradation and biocompatibility of multistage nanovectors in
physiological systems. J Biomed Mater Res A 102, 3540-3549, doi:10.1002/jbm.a.35017 (2014).
303 Low, S. P., et al. The biocompatibility of porous silicon in tissues of the eye. Biomaterials 30,
2873-2880, doi:10.1016/j.biomaterials.2009.02.008 (2009).
304 Godin, B., et  al. Tailoring the degradation kinetics of mesoporous silicon structures through
PEGylation. J Biomed Mater Res A 94, 1236-1243 (2010).
305 Tzur-Balter, A., et al. Mechanism of erosion of nanostructured porous silicon drug carriers in
neoplastic tissues. Nat Commun 6, 6208, doi:10.1038/ncomms7208 (2015).
306 Godin, B., et al. Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast
Cancer Bearing Mice. Adv Funct Mater 22, 4225-4235, doi:10.1002/adfm.201200869 (2012).
307 Riikonen, J., et  al. Systematic in vitro and in vivo study on porous silicon to improve the oral
bioavailability of celecoxib. Biomaterials 52, 44-55, doi:10.1016/j.biomaterials.2015.02.014
(2015).
308 Fry, N. L., et al. Oxidation-induced trapping of drugs in porous silicon microparticles. Chem
Mater 26, 2758-2764 (2014).
309 Kang, J., et al. Self-sealing porous silicon-calcium silicate core-shell nanoparticles for targeted
siRNA delivery to the injured brain. Adv Mater 28, 7962-7969 (2016).
310 Dorvee, J. R., et al. Manipulation of liquid droplets using amphiphilic, magnetic one-dimensional
photonic crystal chaperones. Nat Mater 3, 896 (2004).
311 Correia, A., et al. Cyclodextrin-modified porous silicon nanoparticles for efficient sustained drug
delivery and proliferation inhibition of breast cancer cells. ACS Appl Mater Interfaces 7, 23197-
23204 (2015).
References
74
312 Fan, D., et  al. Mesoporous silicon?PLGA composite microspheres for the double controlled
release of biomolecules for orthopedic tissue engineering. Adv Funct Mater 22, 282-293 (2012).
313 Liu, D., et  al. Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced
cytocompatibility and stability, reduced cellular association, and prolonged drug release. Adv
Funct Mater 23, 1893-1902 (2013).
314 Nan, K., et al. Porous silicon oxide–PLGA composite microspheres for sustained ocular delivery
of daunorubicin. Acta Biomater 10, 3505-3512 (2014).
315 Zhang, H., et  al. Fabrication of a multifunctional nano-in-micro drug delivery platform by
microfluidic templated encapsulation of porous silicon in polymer matrix. Adv Mater 26, 4497-
4503, doi:10.1002/adma.201400953 (2014).
316 Herranz? Blanco, B., et al. On-chip  self-assembly  of  a  smart  hybrid  nanocomposite  for
antitumoral applications. Adv Funct Mater 25, 1488-1497 (2015).
317 Kong, F., et  al. Gold nanorods, DNA origami, and porous silicon nanoparticle-functionalized
biocompatible double emulsion for versatile targeted therapeutics and antibody combination
therapy. Adv Mater 28, 10195-10203, doi:10.1002/adma.201602763 (2016).
318 Liu, D., et al. Microfluidic assisted one-step fabrication of porous silicon@acetalated dextran
nanocomposites for precisely controlled combination chemotherapy. Biomaterials 39, 249-259,
doi:10.1016/j.biomaterials.2014.10.079 (2015).
319 Shrestha, N., et al. Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol
flow reactor technology: A controlled dual protein-drug delivery system. Biomaterials 68, 9-20,
doi:10.1016/j.biomaterials.2015.07.045 (2015).
320 Shrestha, N., et  al. Thiolation and cell-penetrating peptide surface functionalization of porous
silicon nanoparticles for oral delivery of insulin. Adv Funct Mater 26, 3405-3416 (2016).
321 Tamarov, K., et al. Temperature responsive porous silicon nanoparticles for cancer therapy -
spatiotemporal triggering through infrared and radiofrequency electromagnetic heating. J
Control Release 241, 220-228, doi:10.1016/j.jconrel.2016.09.028 (2016).
322 Shrestha, N., et al. Chitosan-modified porous silicon microparticles for enhanced permeability of
insulin across intestinal cell monolayers. Biomaterials 35, 7172-7179,
doi:10.1016/j.biomaterials.2014.04.104 (2014).
323 Zhang, F., et al. Sequential antifouling surface for efficient modulation of the nanoparticle–cell
interactions in protein-rich environments. Adv Ther 1, 1800013 (2018).
324 Zhang, F., et  al. Receptor-mediated surface charge inversion platform based on porous silicon
nanoparticles for efficient cancer cell recognition and combination therapy. ACS Appl Mater
Interfaces 9, 10034-10046, doi:10.1021/acsami.7b02196 (2017).
325 Janoniene, A., et  al. A versatile carbonic anhydrase IX targeting ligand-functionalized porous
silicon nanoplatform for dual hypoxia cancer therapy and imaging. ACS Appl Mater Interfaces
9, 13976-13987, doi:10.1021/acsami.7b04038 (2017).
326 Liu, Z., et al. Quercetin-based modified porous silicon nanoparticles for enhanced inhibition of
doxorubicin-resistant cancer cells. Adv Healthc Mater 6, 1601009 (2017).
327 Reuter, L. J., et al. Coating nanoparticles with plant-produced transferrin–hydrophobin fusion
protein enhances their uptake in cancer cells. Bioconjug Chem 28, 1639-1648 (2017).
328 Almeida, P. V., et al. A multifunctional nanocomplex for enhanced cell uptake, endosomal escape
and improved cancer therapeutic effect. Nanomedicine (Lond), doi:10.2217/nnm-2017-0034
(2017).
329 Kong, F., et  al. Inhibition  of  multidrug  resistance  of  cancer  cells  by  co-delivery  of  DNA
nanostructures and drugs using porous silicon nanoparticles@giant liposomes. 25, 3330-3340
(2015).
330 Wang, C. F., et  al. Dual-drug delivery by porous silicon nanoparticles for improved cellular
uptake, sustained release, and combination therapy. Acta Biomater 16, 206-214,
doi:10.1016/j.actbio.2015.01.021 (2015).
331 Wang, C. F., et  al. Multifunctional porous silicon nanoparticles for cancer theranostics.
Biomaterials 48, 108-118, doi:10.1016/j.biomaterials.2015.01.008 (2015).
332 Almeida, P. V., et al. Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles
for targeting breast cancer tumors. Nanoscale 6, 10377-10387, doi:10.1039/c4nr02187h (2014).
333 Tolli, M. A., et al. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the
heart. Biomaterials 35, 8394-8405, doi:10.1016/j.biomaterials.2014.05.078 (2014).
334 Kinnari, P. J., et al. Tumour homing peptide-functionalized porous silicon nanovectors for cancer
therapy. Biomaterials 34, 9134-9141, doi:10.1016/j.biomaterials.2013.08.034 (2013).
335 Scavo, M. P., et al. Multistage vector delivery of sulindac and silymarin for prevention of colon
cancer. Colloids Surf B Biointerfaces 136, 694-703, doi:10.1016/j.colsurfb.2015.10.005 (2015).
336 Mi, Y. et al., Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol
Res 113, 92-99, doi:10.1016/j.phrs.2016.08.024 (2016).
337 Wolfram, J., et al. Multistage vector (MSV) therapeutics. J Control Release 219, 406-415,
doi:10.1016/j.jconrel.2015.08.010 (2015).
References
75
338 Tanaka, T., et  al. Sustained small interfering RNA delivery by mesoporous silicon particles.
Cancer Res 70, 3687-3696, doi:10.1158/0008-5472.CAN-09-3931 (2010).
339 Tasciotti, E., et al. Mesoporous silicon particles as a multistage delivery system for imaging and
therapeutic applications. Nat Nanotechnol 3, 151 (2008).
340 Ferreira, M. P. A., et al. Drug-loaded multifunctional nanoparticles targeted to the endocardial
layer of the injured heart modulate hypertrophic signaling. Small 13,
doi:10.1002/smll.201701276 (2017).
341 Ferreira, M. P.,  et  al. In  vitro  and  in  vivo  assessment  of  heart-homing  porous  silicon
nanoparticles. Biomaterials 94, 93-104, doi:10.1016/j.biomaterials.2016.03.046 (2016).
342 Martins, J. P., et al. Engineered multifunctional albumin-decorated porous silicon nanoparticles
for FcRn translocation of insulin. Small 14, e1800462, doi:10.1002/smll.201800462 (2018).
343 Araujo, F., et  al. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl
peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.
Nanoscale 8, 10706-10713, doi:10.1039/c6nr00294c (2016).
344 Shrestha, N., et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites
in a diabetic animal model. J Control Release 232, 113-119, doi:10.1016/j.jconrel.2016.04.024
(2016).
345 Li, W., et al. GDNF mimetics delivery by porous silicon nanoparticles for improved Parkinson’s
disease management. Nanomedicine: NBM 14, 1848 (2018).
346 Liu, Z., et  al. Multifunctional nanohybrid based on porous silicon nanoparticles, gold
nanoparticles, and acetalated dextran for liver regeneration and acute liver failure theranostics.
Adv Mater 30, e1703393, doi:10.1002/adma.201703393 (2018).
347 Ainslie, K. M., et al.  In vitro immunogenicity of silicon-based micro- and nanostructured surfaces.
ACS Nano 2, 1076-1084, doi:10.1021/nn800071k (2008).
348 Jurkic, L. M., et al. Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic
acid-releasing compounds: New perspectives for therapy. Nutr  Metab  (Lond) 10, 2,
doi:10.1186/1743-7075-10-2 (2013).
349 Xia, X., et al. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-
presentation and inducing type I interferon response. Cell Rep 11, 957-966,
doi:10.1016/j.celrep.2015.04.009 (2015).
350 Meraz, I. M., et  al. Activation of the inflammasome and enhanced migration of microparticle-
stimulated dendritic cells to the draining lymph node. Mol Pharm 9, 2049-2062,
doi:10.1021/mp3001292 (2012).
351 Meraz, I. M., et  al. Multivalent presentation of MPL by porous silicon microparticles favors T
helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes. PLoS One
9, e94703, doi:10.1371/journal.pone.0094703 (2014).
352 Gu, L., et al. Multivalent porous silicon nanoparticles enhance the immune activation potency of
agonistic CD40 antibody. Adv Mater 24, 3981-3987, doi:10.1002/adma.201200776 (2012).
353 Shahbazi, M.-A., et  al. A prospective cancer chemo-immunotherapy approach mediated by
synergistic CD326 targeted porous silicon nanovectors. Nano Res 8, 1505-1521 (2015).
354 Larson, C., et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget
6, 19976-19989, doi:10.18632/oncotarget.5116 (2015).
355 Muruve, D. A. The innate immune response to adenovirus vectors. Hum Gene Ther 15, 1157-1166,
doi:10.1089/hum.2004.15.1157 (2004).
356 Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev
Immunol 5, 375-386, doi:10.1038/nri1604 (2005).
357 Fukuhara, H., et al. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci
107, 1373-1379 (2016).
358 Coffin, R. Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy
approved for the treatment of cancer. Immunotherapy 8, 103-106 (2016).
359 Pol, J., et al. First oncolytic virus approved for melanoma immunotherapy. OncoImmunology,
e1115641, doi:10.1080/2162402X.2015.1115641 (2016).
360 Kaufman, H. L., et al. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug
Discov 14, 642-662, doi:10.1038/nrd4663 (2015).
361 Lawler, S. E., et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol 3, 841-849,
doi:10.1001/jamaoncol.2016.2064 (2017).
362 Russell, S. J., et al. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33, 599-
605 (2018).
363 Andtbacka, R. et al. Talimogene laherparepvec improves durable response rate in patients with
advanced melanoma. J Clin Oncol 33, 2780-2788 (2015).
364 Long, G. V., et  al. Efficacy  analysis  of  MASTERKEY-265  phase  1b  study  of  talimogene
laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
J Clin Oncol, doi:10.1200/JCO.2016.34.15_suppl.9568 (2016).
References
76
365 Hou, W., et al. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by
targeting of VEGF. Int J Cancer 135, 1238-1246 (2014).
366 Breitbach, J. C. J., et  al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in
humans. Cancer Res (2013).
367 Liu, T.-C., et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular,
and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16, 1637-1642
(2008).
368 Lichty, B. D., et al. C. Going viral with cancer immunotherapy. Nat Rev Cancer 14, 559-567,
doi:10.1038/nrc3770 (2014).
369 Mell, L. K., et al. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin
and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer
Res, clincanres. 3232.2016 (2017).
370 Breitbach, C. J., et  al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic
poxvirus in humans. Nature 477, 99 (2011).
371 Tesfay, M. Z., et al. PEGylation of vesicular stomatitis virus (VSV) extends virus persistence in
blood circulation of passively immunized mice. J Virol, JVI. 02832-02812 (2013).
372 O'Riordan, C. R., et al. PEGylation of adenovirus with retention of infectivity and protection from
neutralizing antibody in vitro and in vivo. Hum Gene Ther 10, 1349-1358 (1999).
373 Morrison, J., et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to
the epidermal growth factor receptor. Mol Ther 16, 244-251 (2008).
374 Lu, S. Heterologous prime–boost vaccination. Curr Opin Immunol 21, 346-351 (2009).
375 Pol, J. G., et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther 22, 420-429 (2014).
376 Ungerechts, G., et  al. Moving oncolytic viruses into the clinic: clinical-grade production,
purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev 3,
16018, doi:10.1038/mtm.2016.18 (2016).
377 Kirn, D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in
cancer. Oncogene 19, 6660-6669, doi:10.1038/sj.onc.1204094 (2000).
378 Harrison, S. C. Virology. Looking inside adenovirus. Science 329, 1026-1027,
doi:10.1126/science.1194922 (2010).
379 Yamamoto, M. et al. Current issues and future directions of oncolytic adenoviruses. Mol Ther 18,
243-250 (2010).
380 Mathis, J. M., et al. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 24,
7775-7791, doi:10.1038/sj.onc.1209044 (2005).
381 Jiang, H., et al. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune
checkpoints. Curr Opin Virol 13, 33-39 (2015).
382 Pol, J., et  al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 3, e28694
(2014).
383 Capasso, C., et  al. Oncolytic  adenoviruses  coated  with  MHC-I  tumor  epitopes  increase  the
antitumor immunity and efficacy against melanoma. Oncoimmunology 5, e1105429 (2016).
384 Bai, Y., et  al. Applications of microfluidics in quantitative biology. Biotechnol J 13, e1700170,
doi:10.1002/biot.201700170 (2018).
385 Sackmann, E. K., et al. The present and future role of microfluidics in biomedical research.
Nature 507, 181-189, doi:10.1038/nature13118 (2014).
386 Elvira, K. S., et al. The past, present and potential for microfluidic reactor technology in chemical
synthesis. Nat Chem 5, 905-915, doi:10.1038/nchem.1753 (2013).
387 Ma, J., et al. Controllable synthesis of functional nanoparticles by microfluidic platforms for
biomedical applications - a review. Lab Chip 17, 209-226, doi:10.1039/c6lc01049k (2017).
388 Riahi, R., et al. Microfluidics for advanced drug delivery systems. Curr Opin Chem Eng 7, 101-
112 (2015).
389 Marre, S., et al. Synthesis of micro and nanostructures in microfluidic systems. Chem Soc Rev
39, 1183-1202, doi:10.1039/b821324k (2010).
390 Rondeau, E. et al. Biopolymer microparticle and nanoparticle formation within a microfluidic
device. Langmuir 24, 6937-6945 (2008).
391 Fontana, F., et al. Microfluidics as a cutting-edge technique for drug delivery applications. J Drug
Delivery Sci Technol 34, 76-87 (2016).
392 Valencia, P. M., et al. Microfluidic technologies for accelerating the clinical translation of
nanoparticles. Nat Nanotechnol 7, 623-629, doi:10.1038/nnano.2012.168 (2012).
393 Liu, D., et al. Current developments and applications of microfluidic technology toward clinical
translation of nanomedicines. Adv Drug Deliv Rev 128, 54-83, doi:10.1016/j.addr.2017.08.003
(2018).
394 Zhao, C. X. Multiphase flow microfluidics for the production of single or multiple emulsions for
drug delivery. Adv Drug Deliv Rev 65, 1420-1446, doi:10.1016/j.addr.2013.05.009 (2013).
395 Whitesides, G. M. The origins and the future of microfluidics. Nature 442, 368-373,
doi:10.1038/nature05058 (2006).
References
77
396 Liu, D., et al. Microfluidic-assisted fabrication of carriers for controlled drug delivery. Lab Chip
17, 1856-1883, doi:10.1039/c7lc00242d (2017).
397 Martins, J. P., et al. The importance of microfluidics for the preparation of nanoparticles as
advanced drug delivery systems. Expert Opin Drug Delivery 15, 469-479 (2018).
398 Pessi, J., et  al. Microfluidics-assisted engineering of polymeric microcapsules with high
encapsulation efficiency for protein drug delivery. Int  J  Pharm 472, 82-87,
doi:10.1016/j.ijpharm.2014.06.012 (2014).
399 Araujo, F., et al. Microfluidic assembly of a multifunctional tailorable composite system designed
for site specific combined oral delivery of peptide drugs. ACS Nano 9, 8291-8302,
doi:10.1021/acsnano.5b02762 (2015).
400 Herranz-Blanco, B., et  al. Microfluidic assembly of multistage porous silicon–lipid vesicles for
controlled drug release. Lab Chip 14, 1083-1086 (2014).
401 Liu, D., et  al. Microfluidic templated mesoporous silicon–solid lipid microcomposites for
sustained drug delivery. ACS Appl Mater Interfaces 5, 12127-12134 (2013).
402 Bertoni, S., et al. pH and reactive oxygen species-sequential responsive nano-in-micro omposite
for targeted therapy of inflammatory bowel disease. Adv Funct Mater, 1806175 (2018).
403 Li, W., et al. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed
sites of intestine. Biomaterials 185, 322-332, doi:10.1016/j.biomaterials.2018.09.024 (2018).
404 Liu, D., et al. A versatile and robust microfluidic platform toward high throughput synthesis of
homogeneous nanoparticles with tunable properties. Adv Mater 27, 2298-2304 (2015).
405 Liu, D., et  al. Core/shell nanocomposites produced by superfast sequential microfluidic
nanoprecipitation. Nano Lett 17, 606-614, doi:10.1021/acs.nanolett.6b03251 (2017).
406 Sarparanta, M., et al. (1)(8)F-labeled modified porous silicon particles for investigation of drug
delivery carrier distribution in vivo with positron emission tomography. Mol Pharm 8, 1799-
1806, doi:10.1021/mp2001654 (2011).
407 Bimbo, L. M., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles
and their biodistribution in rats. ACS Nano 4, 3023-3032, doi:10.1021/nn901657w (2010).
408 Kovalainen, M., et  al. Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi
microparticle surface chemistry on peptide YY3-36 release. Pharm Res 29, 837-846,
doi:10.1007/s11095-011-0611-6 (2012).
409 Bimbo, L. M., et  al. Drug  permeation  across  intestinal  epithelial  cells  using  porous  silicon
nanoparticles. Biomaterials 32, 2625-2633 (2011).
410 Herranz-Blanco, B., et al. Microfluidics platform for glass capillaries and its application in
droplet and nanoparticle fabrication. Int J Pharm 516, 100-105,
doi:10.1016/j.ijpharm.2016.11.024 (2017).
411 Kanerva, A., et  al. Targeting adenovirus to the serotype 3 receptor increases gene transfer
efficiency to ovarian cancer cells. Clin Cancer Res 8, 275-280 (2002).
412 Kanerva, A,. et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-
targeted oncolytic adenovirus. Mol Ther 8, 449-458 (2003).
413 Shahbazi, M. A., et  al. The mechanisms of surface chemistry effects of mesoporous silicon
nanoparticles on immunotoxicity and biocompatibility. Biomaterials 34, 7776-7789,
doi:10.1016/j.biomaterials.2013.06.052 (2013).
414 Liu, D., et al. Impact of pore size and surface chemistry of porous silicon particles and structure
of phospholipids on their interactions. ACS  Biomater  Sci  Eng 4, 2308-2313,
doi:10.1021/acsbiomaterials.8b00343 (2018).
415 Luk, B. T., et  al. Interfacial interactions between natural RBC membranes and synthetic
polymeric nanoparticles. Nanoscale 6, 2730-2737 (2014).
416 Suk, J. S., et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene
delivery. Adv Drug Deliv Rev 99, 28-51 (2016).
417 Yang, Q. et al. Anti-PEG immunity: emergence, characteristics, and unaddressed questions.
Wiley Interdiscip Rev Nanomed Nanobiotechnol 7, 655-677, doi:10.1002/wnan.1339 (2015).
418 Behzadi, S., et  al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev 46,
4218-4244, doi:10.1039/c6cs00636a (2017).
419 Iversen, T.-G., et al. Endocytosis and intracellular transport of nanoparticles: present knowledge
and need for future studies. Nano Today 6, 176-185 (2011).
420 Bachelder, E. M., et al. Acetalated dextran: a tunable and acid-labile biopolymer with facile
synthesis and a range of applications. Chem Rev 117, 1915-1926,
doi:10.1021/acs.chemrev.6b00532 (2017).
421 Mailliard, R. B., et  al. alpha-type-1  polarized  dendritic  cells:  a  novel  immunization  tool  with
optimized CTL-inducing activity. Cancer Res 64, 5934-5937, doi:10.1158/0008-5472.CAN-04-
1261 (2004).
422 Kuzu, O. F., et al. Current state of animal (mouse) modeling in melanoma research. Cancer
Growth Metastasis 8, 81-94, doi:10.4137/CGM.S21214 (2015).
References
78
423 Smyth, M. J., et al. Combination cancer immunotherapies tailored to the tumour
microenvironment. Nat Rev Clin Oncol 13, 143-158, doi:10.1038/nrclinonc.2015.209 (2016).
424 Sharma, P. et al. Immune checkpoint targeting in cancer therapy: toward combination strategies
with curative potential. Cell 161, 205-214, doi:10.1016/j.cell.2015.03.030 (2015).
425 Yang, R.. et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification
for effective anticancer vaccination. ACS Nano 12, 5121-5129, doi:10.1021/acsnano.7b09041
(2018).
47/2019
Helsinki 2019                      ISSN 2342-3161                 ISBN 978-951-51-5286-2       
Recent Publications in this Series
29/2019 Agnes Stenius-Ayoade
Housing, Health and Service Use of the Homeless in Helsinki, Finland
30/2019 Mari Metsäniitty
Forensic Age Assessment in Finland, and Dental Development of Somalis
31/2019 Heli Tolppanen
Prognostication in Acute Heart Failure and Cardiogenic Shock― Focus on Electrocardiography 
and Biomarkers
32/2019 Olli-Pekka Pulkka
Novel Therapeutic Targets in Gastrointestinal Stromal Tumor
33/2019 Inkeri Spoljaric
GABAergic Signaling and Neuronal Chloride Regulation in the Control of Network Events in the 
Immature Hippocampus
34/2019 Nina Mars
Healthcare Utilization in Rheumatic Diseases 
35/2019 Katrina Albert
Modelling Alpha-Synuclein-Based Parkinson’s Disease and Studies with CDNF
36/2019 Felix Siebenhühner
The Role of Multi-Scale Phase Synchronization and Cross-Frequency Interactions in Cognitive 
Integration
37/2019 Elisa Saarnio
Associations among Vitamin D Binding Protein Gene Polymorphisms, Total, Free and 
Bioavailable 25-Hydroxyvitamin D, and Skeletal Outcomes ─ Studies in Children, Adolescents, 
and Middle-Aged Finns
38/2019 Ulrika Julku
Prolyl Oligopeptidase and Alpha-Synuclein in the Regulation of Nigrostriatal Dopaminergic 
Neurotransmission
39/2019 Reijo Siren
Screening for Cardiovascular Risk Factors in Middle-Aged Men: The Long-Term Effect of 
Lifestyle Counselling
40/2019 Paula Tiittala
Hepatitis B and C, HIV and Syphilis among Migrants in Finland: Opportunities for Public 
Health Response
41/2019 Darshan Kumar
Reticulon Homology Domain Containing Protein Families of the Endoplasmic Reticulum
42/2019 Iris Sevilem
The Integration of Developmental Signals During Root Procambial Patterning in Arabidopsis 
thaliana
43/2019 Ying Liu
Transcriptional Regulators Involved in Nutrient-Dependent Growth Control
44/2019 Ramón Pérez Tanoira
Race  for the Surface ― Competition Between Bacteria and Host Cells in Implant Colonization 
Process
45/2019 Mgbeahuruike Eunice Ego
Evaluation of the Medicinal Uses and Antimicrobial Activity of Piper guineense (Schumach & 
Thonn)
46/2019 Suvi Koskinen
Near-Occlusive Atherosclerotic Carotid Artery Disease: Study with Computed Tomography
Angiography
FLAV
IA
 FO
N
TA
N
A
   BIO
H
YBRID
 CLO
A
KED
 N
A
N
O
VA
CCIN
ES FO
R CA
N
CER IM
M
U
N
O
TH
ERA
PY
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis
DRUG RESEARCH PROGRAM
DIVISION OF PHARMACE TICAL CHEMISTRY AND TECHNOLOGY
FACULTY OF PHARMACY
DOCTORAL PROGRAMME IN DRUG RESEARCH
UNIVERSITY OF HELSINKI
BIOHYBRID CLOAKED NANOVACCINES FOR CANCER 
IMMUNOTHERAPY
FLAVIA FONTANA
U
